Podcasts about interim chief executive officer

The Cairngorm Funicular Railway is back up and running after some extensive structural works. Mark took a trip up to the snow-covered peak with the Interim Chief Executive Officer of Cairngorm Mountain Scotland Limited, Tim Hurst, to find out what impact the funicular has for the mountain resort.Farmers and land managers are working together in Moray to investigate how they can tackle environmental challenges such as flooding and decline of biodiversity in the area. Rachel is with Ron Oliveira from Shempton Farms and Charlie Davis from Sylvestris Land Management at Balormie Marsh to hear how their efforts are going.Duke Christie is an artist and cabinet maker based in Moray, who has featured his work in galleries and design showcases across the world and is renowned for his unique use of fire. Mark met up with him at his workshop to learn more about his craft.Historic Environment Scotland recently granted Category A Listed Status to the Glasgow Central Mosque. The building was the first in Scotland to utilise Islamic architectural traditions, articulating these with Glasgow's typical red sandstone. Mark met up with Omar Afzal to hear more about the mosque's design and the important role the mosque plays in Glasgow's Muslim community.Rachel meets up with a colleague and regular Out of Doors contributor Linda Sinclair, after she has recently received a Police Scotland bravery award for her efforts in rescuing a woman from the sea in Orkney.Students from the Sculpture and Environmental Art course at Glasgow School of Art staged a pop-up exhibition at Lang Craigs in Dumbarton, utilising the landscape and environment in their installations. Rachel met up with the students to learn more about the inspiration for their projects and the history behind this transient exhibition.There have been reindeer on the slopes of Cairngorm for over 70 years, with the first animals being established in the area in 1952. Now, the centre has undergone significant renovations, moving into a purpose built centre, complete with paddocks and exhibitions. Mark met with Co-Director of the Cairngorm Reindeer Centre Tilly Smith to hear more about this project and how it feels to move the centre out from its original location - the front room of her house!David Atthowe of outdoor exploration company Reveal Nature is an expert in revealing some of the hidden markings and patterns of the world around us using the magic of UV light. Paul English went along to a late night tour in Bute Community Forest in Argyll to see some of this biofluorescence for himself

This is the first episode of 2025. In this episode, Clare and Gilbert Valleys Council Interim CEO Andrew Aitken discusses:CEO appointment updateCouncils view on reducing dust on roads during dry timesDiscovery Caravan Park seeking approval for park improvementsRepresentation Review final reportOff street parking request by Model Engineers for Phoenix Ave, ClareSuccessful applicants for Community Asset grants**NEW CEO APPOINTED****Clare and Gilbert Valleys Council is pleased to announce the appointment of David Stobbe to the role of Chief Executive Officer.At its special meeting of Wednesday, 26 February 2025, Council finalised itsrecruitment for the role following an extensive and robust recruitment process.Understanding that this is a highly anticipated announcement, Mayor AllanAughey OAM said Council welcomed the appointment, noting that the Councillors feel David will play an important role in supporting Clare and Gilbert Valleys in building upon its strategic direction, and achieving a number of key infrastructure projects to meet the needs of the communityDavid joins Council from the City of Onkaparinga, where he held the position of Director Corporate and Chief Financial Officer. Whilst possessing an extensive financial background, David is also extremely community focused, holding a number of board positions, including the Country Fire Service (CFS) Foundation, the Central District Football Club, and Harness Racing South Australia.David will be relocating to the District and is thrilled at the prospect of joining at Clare and Gilbert Valleys Council, commencing 31 March 2025. He is eager to work with the community to create a lasting impact,  and looks forward to collaborating with Council, local businesses, residents and other stakeholders to drive positive change, enhance services, and support a strong and vibrant future for all.With the appointment of the Chief Executive Officer brings an end to the interim arrangement.Council takes this time to thank Interim Chief Executive Officer, Andrew Aitken, for his sincere and collaborative leadership over the past five months. Much has been achieved under his steady guidance and this will assist David in his transition to the Clare and Gilbert Valleys.Water carting in the Clare and Gilbert Valleys It's no surprise to anyone in SA, it's so incredibly dry, to the point people have been repeatedly carting water to fill up their tanks. In the Adelaide Hills we've heard there's a 2-month waiting list to get water delivered, with SA Water opening a few potable stations to allow more access to water.In the Clare and Gilbert Valleys region, local water carter, Grant Fidge has been flat out delivering up to an average 80 thousand litres to residents across the Clare and Gilbert Valley region.He says there is a 3 week wait for water.Grant Fidge, Fidges Water CartingDesperate calls for more volunteer mentors for Wheels in MotionTo get your provisional drivers licence you need to rack up 75 hours of driving time. For most young people, that's a challenge. But there are many in the community that are struggling to get their P's because they don't have anyone at home to help supervise their driving.  That's where Wheels in Motion comes in, a program that started in February last year providing volunteer mentors to help young people get their driving hours up. Unfortunately, one year on, demand is outstripping supply with a waiting list of young people but not enough mentors. In Clare Valley alone, there are currently 12 participants and 10 mentors with 6 more participants on the waiting list.Christina Underdown, Program coordinator; Bron Willis, mentor; Gareth Herron, mentor

The National Congress of American Indians hosts a panel on healthcare priorities at its executive council winter session on February 12, 2025. PARTICIPANTS A.C Locklear, Interim Chief Executive Officer, National Indian Health Board Francys Crevier, JD, Chief Executive Officer, National Council of Urban Indian Health Meredith Raimondi, Vice President of Policy and Communications, National Council of Urban Indian Health (Moderator) NCAI's meeting took place in Washington, D.C.

02/06/25: Joel Heitkamp is joined in the KFGO studio by Pastor Devlyn Brooks, the Interim Chief Executive Officer of Churches United. Learn more and donate to Churches United here!See omnystudio.com/listener for privacy information.

As President of the University of Miami and CEO of UHealth, Joe Echevarria leads more than 20,000 professionals whose focus is transforming lives through education, research, and patient care.A seasoned chief executive, Mr. Echevarria served as the CEO of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36-year tenure with the firm, he served in various leadership roles, including Deputy Managing Partner, Southeast Region, Audit Managing Partner, and U.S. Managing Partner and Chief Operating Officer. His leadership responsibilities extended to approximately 70,000 professionals in nearly 90 U.S. cities and India, as well as the firm's US-owned consulting businesses in Germany, Mexico, China, and Brazil.Mr. Echevarria has a long history of service to the University of Miami, where he earned a bachelor's degree in business administration in 1978.  Following his retirement from Deloitte and seven years of service on its Board of Trustees from 2012 to 2019, Echevarria brought his expertise to the University of Miami Health System as a Senior Advisor to former President Julio Frenk, Interim Chief Financial Officer, Chief Administrative Officer, and Interim Chief Executive Officer. He became Chief Executive Officer of UHealth in 2020 and his responsibilities as CEO grew to include the entire University in 2022. On June 12, 2024, the University of Miami Board of Trustees appointed him Acting President of the University.

Minister for Further and Higher Education, Research, Innovation and Science Patrick O'Donovan TD, has announced funding of €26 million for 40 research projects. Funded under the Taighde Éireann - Research Ireland Frontiers for the Future Programme, the projects address key areas such as environmental sustainability, new EV battery technologies, breast cancer, inflammatory bowel disease, and currently untreatable childhood neurological disorders. As a Frontiers for the Future partner, the Children's Health Foundation is funding two of the 40 projects (childhood epilepsy and cystic fibrosis) and co-funding another project with Research Ireland (bone cancer). Welcoming the announcement, Minister O'Donovan said, "I am pleased to announce the Research Ireland Frontiers for the Future projects, which support high-risk, high-reward research endeavours. The selected projects, spanning 12 research institutions, bring fresh and innovative ideas that will help boost business and benefit society." "I would also like to commend Research Ireland and the Children's Health Foundation for their great partnership and their focus on advancing children's health through this funding program. I encourage others to create similar partnerships and collaborations." Among the other projects to receive funding are: A gene therapy combined with tissue engineering to reduce scarring and help promote nerve regeneration after spinal cord injury Understanding the stability of large ice sheets in Greenland and Antarctica in response to global warming Novel therapies for severe, currently untreatable childhood-neurological disorders Alternative Battery Technologies for Electric Vehicles Assistance dogs with collar sensors to signal and alert impending seizures patients and their carers Studying preserved bog plants to better understand what drought bogs can survive Biosensors in 4D food printing that indicate the strength and stability of probiotics Celine Fitzgerald, Interim Chief Executive Officer of Research Ireland, commented: "The Research Ireland Frontiers for the Future programme helps to build research capacity, expertise and reputation. This latest round of grants will support a diverse range of research positions and represents a strong commitment to developing future talent in key areas. It has been a pleasure having Children's Health Foundation as a funding partner in that drive to strengthen Ireland's research pipeline." Fionnuala O'Leary, Chief Executive Officer of Children's Health Foundation, commented: "Children's Health Foundation is a proud partner of Frontiers for the Future programme, and we are delighted to co-fund paediatric research projects that will benefit sick children throughout Ireland. Working with Research Ireland, we are able to leverage the funds our incredible supporters raise to deliver larger grants for research into childhood diseases. This ensures the tireless efforts of our fundraisers can result in kinder and more gentler treatments for sick children. Frontiers for the Future programme plays a key role in enabling us to fund paediatric research with the potential to deliver impact for sick children now and into the future." The research will be undertaken in the following research bodies for 2-4 years: University College Cork Dublin Institute for Advanced Studies University of Limerick University College Dublin Trinity College Dublin University of Galway Technological University Dublin Dublin City University Tyndall National Institute Teagasc Maynooth University RCSI University of Medicine and Health Sciences

In this episode, host Helen Angus, CEO of AMS Healthcare, speaks with Donna Duncan.   Donna Duncan is a passionate seniors' care, mental health advocate, and broader public sector leader, bringing more than 20 years of experience in advancing transformative change at organization and system levels.   As CEO of the Ontario Long Term Care Association, Donna leads the largest provincial association representing long-term care providers in Canada. She also is involved in global forums as a member of the board of directors of the Global Ageing Network and serves on the board of the Canadian Association of Long-Term Care. In addition, Donna hosts the highly-rated podcast, Coming of Age, which is changing the conversation about seniors' care, challenging ageism, and exploring innovations in care and public policy for all of us as we age. She is also a sought-after speaker, guest-lecturer and media commentator on seniors' care, health human resources and public policy. Donna previously served as the Interim Chief Executive Officer of The Ontario Caregiver Organization where she led the organization's start-up operations, building a foundation for new leadership and a provincial board to lead the development of services and supports for family caregivers in Canada's largest province.   In addition, she served as President and CEO of one of Ontario's largest children's mental health treatment, research and teaching centres and also a community affiliate of the University of Toronto. Donna led the organization through transformational change and extensive programmatic and quality improvements, culminating in its integration with The Hospital for Sick Children in 2017 as the SickKids Centre for Community Mental Health. Donna has a deep understanding of healthcare systems and works in partnership with leaders across the health and community care sectors provincially, nationally and internationally. She also has extensive experience within government, having worked with federal and provincial ministers and with a United Nations agency.    Donna currently sits on advisory committees for the Ontario Ministry of Long-Term Care, and on the board of Sunnybrook Health Sciences Centre. She has also served on the boards of The Ontario Caregiver Organization, Children's Mental Health Ontario, the national Kids Brain Health Network, and chaired the Board of Governors of Seneca College and the provincial College Employer Council.   http://amshealthcare.ca/

Philip Watt, Interim Chief Executive Officer, Mental Health Reform, on a call from over 60 organisations for funding to address deficits in the mental health system.

Doing fundraising and communications work more mindfully requires us to move at a slower pace, ask multiple people for feedback, and truly listen to what's being shared. Farra Trompeter, Co-Director, is joined by Karen Lundgard, Interim Chief Executive Officer for Girl Scouts of Greater New York, Lindsey Cosgrove, Chief of Staff at Greenwich House, and Sasha Prado, CFRE, Senior Manager of Major Gifts at Robin Hood, to chat about their work with Girl Scouts of Greater New York's Troop 6000. They share tools and processes to address problematic language and images in marketing and fundraising contexts.

The Community Chest has joined the Western Cape Disaster Management Centre and the City of Cape Town Disaster and Risk Management Centre in the massive humanitarian relief efforts to assist those affected by the storms. Lester Kiewit speaks to Interim Chief Executive Officer, Peter Heeger.See omnystudio.com/listener for privacy information.

Connexall addresses traditional hospital concerns such as fall prevention, other patient safety, and reducing alerts. According to Sandy Saggar, Interim Chief Executive Officer, they achieve this through great flexibility. On the one hand, they connect to a wide range of medical devices through standard protocols and remain vendor-neutral, which is important for hospital systems that have to integrate many systems after a merger or acquisition. Saggar is interested in working with emerging technologies (autonomous robots, generative AI, digital assistants) but focuses on improving and deriving the most benefit from existing systems. “What can we do today that can directly influence patient care and care-givers?” he asks. Learn more about Connexall: https://www.connexall.com/ Health IT Community: https://www.healthcareittoday.com/

Prior to joining the faculty at UAB, Dr. Eagerton was a nurse and Chief Nursing Officer for 31 years in the Veterans Health Administration before retiring in October 2017. As Chief Nursing Officer and Interim Chief Executive Officer in VHA hospitals, he led over 3,000 employees and the operations providing care for over 70,000 Veterans. 

Urbanimmersive launches its print media editor solution UiPrint for Real Estate Photographers and Real Estate Agents SAINT-HUBERT, Quebec, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Urbanimmersive Inc. (“Urbanimmersive,” “the Company,” or “UI”) (TSX VENTURE: UI) (OTCQB: UBMRF), a leading provider of 3D digital twin solutions for real estate marketing, is pleased to announce having launched its print media editor solution UiPrint, after months of development, which will allow Urbanimmersive to offer an extensive, user-friendly, rapid and fully customizable online print design solution for real estate agents. This new promising solution is an embodiment of the synergies created by the integration of the print operations of HomeVisit for their state-of-the-art printing facilities in Chantilly, VA, acquired in late 2022. This solution would allow to scale the printing service department at minimal additional cost while deploying the new solution in the Company' other brands across North America. UiPrint offers to design your flyer, brochure, or mailer with a one-stop shop solution including professional templates with a library of eye-catching designs with customizable fonts, colors, and images to market property listings, seamlessly sync of listing photos and floor plans and access to multiple libraries of high-quality images which should allow to elevate real estate marketing. " We believe UiPrint should drive our sales up while retaining and attracting new agents and allow us to stand out again from the crowd by offering a unique and comprehensive set of print marketing solutions. With the sharp price increase in online marketing in recent years, print marketing is today a cost-effective tangible marketing solution that delivers high conversion rate," stated Simon Bedard, Interim Chief Executive Officer and Chief Financial Officer at Urbanimmersive. TSX Venture Exchange has not reviewed this press release and has neither approved nor disapproved the contents of this press release. About Urbanimmersive Urbanimmersive develops and commercializes real estate photography technologies and services focused on redefining industry visual content standards. The Company all-in-one platform enables high-volume photography businesses to increase operational productivity delivering feature-rich 3D tours and floor plans, leading-edge property websites and high-resolution AI-indexed images. The Company operating segments include software (SaaS), 3D photography equipment and, in a growing number of North American cities, technology-powered real estate photography service business units leading the industry photo-shoots standards transformation. Learn more at: www.urbanimmersive.com 

In this episode of Rural Health Leadership Radio, hosted by Dr. Bill Auxier and Sydney Grant, we welcome another young rural health leader, Alana Monson Administrative Fellow at Trinity Health in Des Moines, Iowa. Just months after graduating with a Master's in Health Administration, Alana found herself in the role of interim CEO at Manning Regional Healthcare Center, a critical access hospital close to her hometown in Iowa.  In our conversation, she discusses how she rapidly transitioned her leadership skills, adapting to the role thanks to a lot of trust from her team. Her story is a testament to the potential for young leaders to make significant contributions to healthcare in rural settings. “If you were ever facing a challenge or responsibility that might seem daunting to you, just do it because your future will thank you for the growth” -Alana Monson Alana Monson is an administrative fellow with Trinity Health – MercyOne in Des Moines, Iowa and recently served as Interim Chief Executive Officer for Manning Regional Healthcare Center in Manning, Iowa. Alana grew up in rural Western Iowa and graduated from the University of Iowa with her Bachelor of Business Administration in Accounting in 2020 and Master of Health Administration in 2023.  While pursuing her graduate degree, she worked with classmates to form the Student Association for Rural Health. In addition to her experience as CEO at a critical access hospital, Alana also has experience working for a Medicare administrative contractor, an academic medical center, a health system, and serving on the Iowa Rural Health Association board.

The retail landscape in the Western United States is set to undergo a significant change as a major player announces its final bow. The 99 Cents Only Stores, a retail store chain based in California, known for its extensive reach and affordable merchandise, recently expressed its intent to close its doors permanently across all of its 371 stores. The decision comes in the wake of a challenging economic climate and widening inflationary gaps that have put intense strain on businesses, particularly those operating in the retail industry. Established in the year 1982, the 99 Cents Only Stores have been a steadfast presence in states such as Arizona, Texas, Nevada, and its home ground California. However, an announcement on a recent Thursday indicated that this era of budget retail is reaching its unfortunate end, as all stores across the four states are set to cease operations in the ensuing months. With the temporary reins of the company in the hands of Mike Simoncic, the Interim Chief Executive Officer, he pointed to a myriad of factors that forced the hand of the company towards this closure. The narrative is a familiar one echoing across businesses globally - the aftershocks of the COVID pandemic, and an economy grappling to regain its footing. In a recently issued press release, the company offered insights into how it intends to wind down operations gracefully. Instead of a sudden cessation of business, 99 Cents Only Stores plans to enter into an agreement with Hilco Global. This liaison would facilitate the liquidation of all the merchandise, equipment, and furnishing that fill the stores' shelves and warehouses. At the height of its operation, the 99 Cents Only Stores enjoyed its status as one of the leading discount retailers in the Western US. Its array of product offerings ranged from inexpensive, fresh produce, and daily household essentials, to seasonal and party merchandise, as well as office supplies. However, the impending closure will have ramifications that resonate beyond the cheap shopping aisles and checkout counters. Roughly 17,000 employees currently make up the workforce of this retail chain. This shutdown, thereby, implies that these individuals stand on the precipice of unemployment. The broader context shows an unsettling trend where many California-based retailers have found it difficult to conduct business over the last few years. Various factors have contributed to establishing an environment of adversity for these enterprises. Perhaps foremost among them are the impacts of the COVID-19 lockdowns. With stores shuttered and potential shoppers remaining indoors to curb the spread of the virus, the continuity of retail operations was severely disrupted. Customer footfall fell dramatically, and as a result, so did the revenues. Furthermore, the prevalence of theft, especially in many urban store locations, has proven to be a significant hurdle for retailers. Confronting an already strained economy, these cases of rampant shoplifting only served to compound the financial woes of these businesses. A more shadowy adversary faced by these retailers, and in fact, most businesses recently, has been inflation. As the purchasing power of the dollar weakens, businesses have been finding it increasingly difficult to keep their expenses in check while still providing their goods and services at an affordable rate. These economic and logistical challenges have directly influenced the operations and bottom line of retail businesses. In particular, the challenges faced by the 99 Cents Only Stores are acutely reflective of these broad trends, bringing to fore the issues plaguing much of the retail industry in the nation. The setting sun on the 99 Cents Only Stores is indeed an unfortunate symbol of struggle for many enterprises in challenging times. However, it is a scenario that unflinchingly highlights the urgent call for economic stability and fiscal soundness to assist the survival and growth of businesses across the board. Retailers, just like any other industry, play a crucial role in the economy not just as providers of goods and services, but also as employers and contributors of growth. Hence, it remains imperative to create an environment that fosters the prosperity of businesses, ensuring their stability for the sake of the economy, the job market and ultimately, the wellbeing of our nation's citizens. Real News Now Website Connect with Real News Now on Social Media Facebook: https://www.facebook.com/RealNewsNowApp/ X Twitter: https://twitter.com/realnewsapp Instagram: https://www.instagram.com/realnews/ TikTok: https://www.tiktok.com/@realnewsnowapp Threads: https://www.threads.net/@realnews/ Tumblr: https://www.tumblr.com/realnewsnow Truth Social: https://truthsocial.com/@RealNews YouTube:https://www.youtube.com/@realnewsnowapp End Wokeness: https://endthewokeness.com #realnewsnow See omnystudio.com/listener for privacy information.

Brian Levine has a rich work experience spanning over several years. Brian started their career at Goldman Sachs in 1994 and worked their way up to become a Partner and co-head of Global Equities Trading and Execution Services. At Goldman Sachs, they served on various committees, including the Firmwide Risk Committee, Firmwide Technology Risk Committee, and Securities Division Executive Committee. Brian retired from Goldman Sachs in 2019. Afterwards, they co-founded The Public Health Company in 2020, where they held the position of Co-Founder and Senior Advisor. The Public Health Company specializes in biosecurity and offers a SaaS-enabled service for the management of bio-risks. Currently, Brian is serving as the Interim Chief Executive Officer at Major League Pickleball.Brian Levine completed a Master of Business Administration (MBA) degree at Emory University - Goizueta Business School from 1992 to 1994. Prior to that, they earned a Bachelor of Business Administration (BBA) degree from the University of Florida, where they studied from 1988 to 1992.

Beverly Coberly is the Interim Chief Executive Officer and Karl Bradley is the Leadership & Team Development Specialist of the Extension Foundation, a membership-based non-profit designed to be the engine fueling U.S. Cooperative Extension's advancement in making a more visible and measurable impact in support of education outreach from land-grant universities/colleges located in every state and territory. -- If you haven't yet had the chance, make sure to register for our 2024 Real Leaders Impact Awards. Our Impact Award winners gain access to a values aligned community, credibility through Real Leaders, and access to our network of Impact capital sources. Apply now to claim your discounted application: ⁠https://eunbi5zgbx7.typeform.com/to/XNdfGsS2#app_first_name=xxxxx&company_name=xxxxx&work_email=xxxxx&campaign_name=xxxxx&channel=LN&owner=Z⁠ Also, check out Outsource Access for all of your Virtual Staffing Needs. At an affordable rate you can outsource the work you need to get done at an extremely affordable rate. You can find more info about them here using this link. https://outsourceaccess.com/

Hollie Bunn is the Interim Chief Executive Officer at Growers Edge. She previously served as Executive Vice President/Chief Lending Operations Officer and is the architect of the company's embedded financial software and services products. With Hollie's leadership, her growing team has built a revolutionary platform for the ag industry while furthering the company's mission to help the ag industry adapt and thrive. Bunn is an enthusiastic 30-year veteran of the ag finance industry in the Midwest, having been an instrumental leader at Farm Credit, where she held various positions, including Vice President of Sales Strategy and Regional Vice President. She is a proud proponent of Women in Ag and supports and serves with the local FFA, 4-H, and beekeeping clubs. Hollie's energy is both infectious and boundless making her an excellent strategic leader for Growers Edge. When she's not meeting with her team, funders, or current and future partners, she's active in the gym, hiking, building a new home on her family's farmstead, and managing several thousand honeybees in southwestern Ohio. It has been said. "To be successful, one has to be one of three bees: the queen bee, the hardest working bee, or the bee that looks to the future,” Hollie exudes traits of all three. Hollie Bunn, interim CEO of Growers Edge, joins Mark to discuss the importance of intentionality in both personal and professional life. Holly emphasizes the need for self-awareness and persistence in achieving goals. She also shares her philosophy on work-life balance and how she integrates her personal and professional selves. Holly highlights the challenges and strategies for talent retention in the AgTech industry and the value of feedback in personal and professional growth. She also discusses the importance of communication and connection in a remote work environment. Holly shares her insights on developing managers and creating an intentional culture within organizations.Key Takeaways:Intentionality involves thought and focus in approaching activities, both personally and professionally.Work-life balance is achieved by being fully present in each domain and intentionally switching between them.Talent retention in the AgTech industry requires understanding individuals' aspirations and aligning them with organizational goals.Feedback is a gift that helps individuals stay true to their desired impact and improve their performance.Remote work requires intentional communication and connection to maintain a strong team dynamic.Developing managers involves providing coaching and feedback, as well as encouraging them to connect with employees outside their department.Creating an intentional culture involves sharing personal values, seeking feedback, and aligning organizational goals with employee aspirations.Quotes:"Being intentional means it's not haphazard in the way that I approach what I'm doing." - Holly Bunn"I want to be fully present when I'm at work and very focused on what I'm doing there and the exact same thing when I'm not at work." - Holly Bunn"Feedback is a gift. It keeps me true to the person that I want to be." - Holly Bunn"Remote work requires intentional communication and connection to maintain a strong team dynamic." - Holly Bunn"Creating an intentional culture involves sharing personal values and aligning organizational goals with employee aspirations." - Holly Bunn

As we approach the conclusion of 2023, we reflect on a year that not only signifies our 10-year anniversary but also marks another chapter of The G Word. Throughout the year, guests have joined us fortnightly to share their research, stories, and aspirations for the future of genomic healthcare.  In this special end-of-year episode, Naimah Callachand sits down with Dr Rich Scott, Interim Chief Executive Officer at Genomics England, to look back on the last decade of Genomics England. Tune in as we revisit memorable moments from the 2023 podcast episodes through key quotes, reflecting on the transformative journey of Genomics England. Join us for this insightful recap and a glimpse into the exciting future ahead!  Below are the links to the podcasts mentioned in this episode, in order of appearance:  Adam Rutherford, Laurence Hurst, Cristina Fonseca and Vivienne Parry: Public views on genetics - what have we learnt?  Dr Jack Bartram: Can genomics improve our understanding of childhood cancers?  Helen Webb, Lizzie Mordey, Kirsty Russell and Prabs Arumugam: How can advances in genome sequencing support patients through their sarcoma journey? Vivienne Parry and David Bick: Which conditions will we look for initially in the Generation Study?   Dr Nicola Byrne: What are the challenges of data governance in the digital age?  Chris Wigley: The journey to the Human Genome Project and beyond with Dr Francis Collins   “We're also looking to the future where, as I say, we're proud of the impact that there already has been, and the NHS Genomic Medicine Service is the first national healthcare system to offer whole genome sequencing and that is extraordinary. Thinking about how we can broaden our impact is a really important part of that, and that's thinking about how we can be supportive of genomic technologies broader than just whole genome.”    You can read the transcript below or download it here: Reflecting-on-2023-transcript.docx   Naimah: Welcome to the G Word. Rich: We're in an extraordinary time. The power to analyse genomic data has changed enormously. These are big changes in terms of the, sort of, analytics that AI could bring and the potential to work not just within the UK but with other countries and other big initiatives to make sure that we're answering the questions as best we can. Naimah: I'm your host Naimah Callachand and today we'll be hearing from Rich Scott, Interim CEO for Genomics England. He'll be sharing insights with us from the last year, and we'll be revisiting key moments from earlier podcasts in the year featuring some of the voices that have shaped our discussions. If you enjoyed today's episode we would love your support, please like, share and rate us on wherever you listen to your podcasts. Now let's get into the interview. So, this year we celebrated our ten-year anniversary and as 2023 comes to a close we want to reflect on our achievements not just in the last year but over the last ten. So, Rich first of all can you talk us through where we started in 2013 and where we are now? Rich: It's amazing really to think about how much things have changed in terms of genomics in clinic and in hospitals and then for us as Genomics England over the last ten years. So, actually thinking back ten years ago was only ten years after the Human Genome Project was completed, and when one thinks about what one could do in clinic and those questions you could answer using genomics in clinic. We could see what was coming, we could see these new technologies, next generation sequence in coming, but it was much more dependent on very targeted testing. And now with, you know, our founding project, the 100,000 Genomes Project that Genomics England was founded to deliver in partnership with the NHS we asked the first big question if you like which was how can whole genome sequencing play a role in routine clinical care. And that's now played out where evidence from the project, what we've learnt, the infrastructure we've built, and also evidence from around the world that through the NHS Genomics Medicine Service has now put that into practice and we're working in partnership to help them deliver it. So, it has gone from an idea where we could see this new technology, this potential, to a position where now patients in the NHS with cancer or with rare conditions have whole genome sequencing as a routine part of their clinical care where that's in that national genomic test directory that NHS England have set up. Naimah: Earlier in the year we heard from Dr Adam Rutherford, geneticist, author and broadcaster who commented on how the public perception of genetics and science has evolved over the last few decades. “I've been doing this a long time and I think that when it comes down to it, genetics which is a relatively young science and really in a sophisticated way, you know, a mere few decades old, but what is it at its absolute core, it's thinking about families, it's thinking about inheritance and it's thinking about sex. And these have been the major preoccupations of humans for thousands of years, and it's only really in the last century, really only in the last 30 years or so, that we've had a sophisticated understanding of how these things work, if indeed we have had at all.” Naimah: Let's get back to Rich. Rich, I've already touched briefly on it, but can we dive a bit deeper into the 100,000 Genomes Project and can you tell me a bit more about how it started. Rich: Yes, so the 100,000 Genomes Project as I said was there to ask what role can whole genome sequencing play in understanding medical conditions, you know, is it ready for clinical prime time. And also how can we link routine clinical care to research so that we're not just asking questions with today's knowledge, but we can continue to build that knowledge for the future. So, the 100,000 Genomes Project was driven by that idea that people realising, the government realising and the NHS forming a partnership with us Genomics England to explore that question in real depth. And it's not just about the clinical aspects and the scientific questions, it has also been working with participants and the public to understand how we could do that. And through the 100,000 Genomes Project we worked particularly with patients with cancer and rare conditions to see how we could help make diagnosis and improve care. And also with their consent make their data available in our secure, trusted research environment so that researchers could continue to look for answers that we couldn't answer today, and we continue to do that work for those participants now. Naimah: Next we're going to hear from an interview with Dr Jack Bartram, a Consultant Paediatric Haematologist at Great Ormond Street Hospital for Children. He spoke about the significance and impact of integrating genomics into routine clinical care in diagnosing cancer in children. “If I look back and if I reflect on the last three years, you know, we could probably accurately say at least a quarter of patients it has given us additional information which is either aided in diagnosis or like I had said help risk stratify a patient or potentially reveal a target for a therapy that we didn't know of before. And what this has led to and what we've seen over the last three years or so is that we have actually changed management of patients based on this. So, definitely we've got examples where we scan clarify the diagnosis, we've changed the risk category, or we've identified for example that an unexpected cancer predisposition in a family which has then led onto screening for the family which can then give the family the knowledge to try and do things to either modify the risk of cancer in the family or at least screen for it so they can detect things early to prevent things presenting too late.” Naimah: Okay, now let's talk a little bit about some of the initiatives at Genomics England. Can we talk about how they've progressed and what they might look like in the future. Rich: Yeah, so we really are on a journey both as an organisation but with all of those partners that we work with across the UK system. And one of the great things I think about genomics and genomics in the UK is that the ecosystem that we're in and the strong partnerships that we can form to ask these really big questions. So, if you like when we formed as an organisation we had the questions that we're asking around diagnostic use of whole genome sequencing in the 100,000 Genomes Project. And if you like in our second chapter as we've moved on to support the NHS in delivery of life clinical care we also have been thinking about the other big questions that we need to address. And those have played out and we've been really fortunate to gain the funding and to work in partnership with the NHS and others on these big questions. So, firstly our newborn genomes programme, secondly our diverse data programme and then our cancer 2.0 initiative. And each of them have big questions behind them so that we're saying, you know, where could genomics better support healthcare and move forward and improve care for everyone. Our vision at Genomics England is a world where everyone can benefit from genomic healthcare and each of them is pushing those boundaries, asking those questions in different ways. For the newborns programme the big question is should every newborn baby be offered whole genome sequencing driven particularly by that potential to identify more treatable severe genetic conditions at birth, and if so how should we do that. Again, developing evidence in and around really broadly across the clinical and scientific aspects, but also engaging and understanding public attitudes how we might do that. And really understanding how that might impact on the healthcare system, how it might be delivered in clinical care. For the diverse data initiative we recognise the challenges historically that there have been because of the inequity in terms of the communities who have been engaged with and included in genomic research. And the diverse data initiative aims to both understand where we are today but also to make sure for example the national genomic research library is at least representative of the UK population so that we can work towards again that word that's in our vision, everyone, a world where everyone can benefit from genomic healthcare. And in the cancer 2.0 initiative we've been exploring two really promising areas in terms of cancer genomics. Firstly, exploring different sequencing technologies and in this case partnering with the NHS to work on the Oxford Nanopore technology which we think is really promising in terms of use in diagnostics to speed up and better diagnose and treat cancers. And also looking in our multimodal element of our cancer 2.0 initiative at bringing in a broader range of data alongside the genomic and clinical data that participants in our programme consent to us holding in our trusted research environments. And bringing in image data, images of their tumours on the histopathology slides that are looked at traditionally down a microscope but scanning those at very high resolution and with uniformity between participants working with NPIC to do that. And also bringing in imaging, so radiology type imaging, of tumours so that that data is there to drive new discovery. And working in partnership with academics and with industry for example insitro to understand how we can both bring that data together usefully, put the right tools next to it and then allow that discovery so that our participants know that we're looking not just on what we know today but to improve things for the future. Naimah: Rich mentioned some of our initiatives here at Genomics England. And now we're going to hear from some G Word guests on how these programmes can make a difference for those with a genetic diagnosis. We spoke to Lizzy Mordey, a clinical trials co-ordinator, whose husband Steve sadly passed away last year after receiving a sarcoma diagnosis. Lizzy commented on the pivotal role whole genome sequencing can play in receiving a quicker diagnosis on the identification of suitable treatments for patients with sarcoma. “Personally, I would hope for quicker diagnosis, and I know that's super hard to do and I think as we've discussed before on this call it's such a rare thing and it, kind of, often doesn't fit the standard clinical pathway and that's one of the reasons why it's so frustrating. So, anything that we can do on that front that I think would be hugely valuable to anyone experiencing a journey like what me and Steve went through, and yes advances like genome sequencing are really amazing in supporting that. Yes, as I mentioned as well any information about types of treatment, you know, the diagnosis is important but then the other aspect of getting a diagnosis and a specific diagnosis is understanding what's most likely to help.” Naimah: Next we're going to hear from David Bick who is a principal clinician for the Newborn Genomes Programme at Genomics England. He spoke about the generation study which is being delivered in partnership with the NHS. “I'm doing this because I imagine a day when all over the world we will find and treat children before they get ill. This is one of the most wonderful programmes to be involved with because I can see that future. I want there to be a healthcare system. I really want to help children stay healthy and really live their best lives, that's what's so exciting for me.” Naimah: Now let's get back to the interview with Rich. You mentioned all of the partnerships there and also one important one is with the NHS. As you know the NHS also celebrated its 75th anniversary year as well as our tenth anniversary. And I wondered if you could tell me a bit more about that relationship with Genomics England and the NHS and how we're working together.  Rich: Our relationship with the NHS is absolutely critical. So, as we're thinking about what we can do to enable better genomic healthcare we're so fortunate in this country to have a national healthcare system. And for us and for our work at Genomics England it's absolutely critical to work hand in hand with NHS England both in supporting their live clinical services so we enable their national whole genome sequencing service through the Genomic Medicine Service and also as we work through all of our patient facing research. So, as we did for the 100,000 Genomes Project, as we are for our Newborn Genomes Programme and so forth co-designing these programmes so that the evidence that we're able to generate is relevant in the UK for our healthcare system but also that national scale is just so extraordinarily powerful. And I think we're really lucky for many reasons, the UK genomics ecosystem, it's richness, the investment that has come from government and from the NHS in genomics and the recognition of its importance and from funders, and then that ability to ask questions at national scale. And when you look internationally I think that's the piece that people are often most jealous of in terms of the power of the questions that we can ask together with the NHS so that we can do exactly what we want to do which is transform care so that it's better in the future. Naimah: Rich highlighted the importance of our relationship with the NHS in transforming patient care. Louise Fish, CEO of Genetic Alliance UK commented on the importance of joined up care following diagnosis to support them throughout their lives. “So, there is a lot more we need to do to work with the NHS to make sure that the care from the health service is joined up and co-ordinated for people. And then beyond that how does the co-ordination reach out to education, to housing, to benefits, to social care. The bit that almost should be simplest is if the NHS has someone who understands your child's condition. But it should be possible for their school to be in touch and to find out how that condition is going to affect them and what support the school might need to put in place through an education health and care plan, but those links out to the other services aren't there either. So, for us there is a lot of work to do that's not just around the diagnosis but it's about ensuring that lifelong care and support is delivered in a co-ordinated way. And as more people are getting genetic diagnosis through this amazing, kind of, clinical advances how do we make sure there is also investment into the clinical services that are going to support people throughout their lives.” Naimah: One of the key factors in supporting Genomics England to deliver this important work and all of our initiatives is the participants and the trust that they have in us. I wondered if you could share a bit more on this, so how Genomics England works with their participant panel. Rich: Yes, so I think one of the things I'm proudest about at Genomics England and it was established about the time I was arriving at the organisation is the participant panel who are a group of our participants who represent a broader participant across the national genomic research library. And they're a part of our governance, which governance sounds like a boring word, our relationship with the participant panel and their role in our governance is absolutely critical. They are the people whose data we are the custodians of, and we have a responsibility to them to live up to their expectations and also to make sure that they're driving the decisions that we're making. An example is how we setup the access to data for researchers. So, I mentioned that the way the national genomic research library works and a model that we developed through engagement with the public and with the input of our participants is that people can visit the de-identified data in our trusted research environment, but they can't take it away. They come and look at the data, they carry out their research which is on approved projects that is exploring healthcare questions. Those researchers have to go through an access process overseen by an independent access review committee that has our participants on it. So, they are making the decisions about the sort of research that they are comfortable with and that they want to be done on their data, and I think that's really critical. It has also been a real pleasure to work with our participants as we design future programmes either on for example finding further answers or looking for better treatments for people who are already in the national genomic research library, already a part of our participants or to help us design future programmes, for example our Newborn Genomes Programme. Our participants as well as engagement with potential future participants and the public more broadly has been absolutely critical in guiding us on how we do that. It's a team sport what we're doing in many different ways. That's with our broader ecosystem, it's with our participants, and that means this isn't about some people going away and sort of thinking up what sounds like the right programme and using all of their knowledge and expertise and producing something which is set in stone. This is about dialogue and engagement and using that to understand the right way of us approaching the questions we are and responding to what we hear. And our participant panel are absolutely critical in that. Naimah: And maybe it would be good now to discuss a bit about the new challenges that we're currently facing such as AI and issues with data sharing and data protection. Can you comment a bit on that. Rich: Yeah, so genomics is a fast moving area. We're really proud of the impact that we've had already, but we also recognise that at the moment we can only use genomics in a particular number of clinical situations. And even within those we can only help a certain proportion of patients. And what our participants say to us is that we need to be restless if you like and not accept where we are today. I think it's quite easy to merely celebrate progress but it's really important to also then ask where we need to be going next. I'm always guided by our participants thinking about what the new technologies are and what the different ways of approaching these scientific questions is critical. We're in an extraordinary time, genomic technology has changed enormously. The power to analyse genomic data has changed enormously. These are big changes in terms of the sorts of analytics that AI could bring and the potential to work not just within the UK but with other countries and other big initiatives to make sure that we're answering the questions as best we can. That brings with it as with all of these areas questions about how you best do things and how you balance the importance of privacy, data privacy, with the benefits of being able to look across larger number of research participants to find answers that you just wouldn't otherwise. Likewise with AI there is the potential for us to both speed up current processes but also ask broader questions that we can't yet using some of these technologies. Doing that in conversation with our participants and the public to understand how to best balance the different benefits and also clarify where there are, sort of, very clear expectations that we shouldn't exceed is really important. And I think that's one of the things that puts us in such a strong position is that confidence that our participants are guiding us and often, and speaking as a doctor myself, it's interesting the medical community is often quite paternalistic, quite cautious and quite narrow in what they might think their participants would want. What we like to do is be driven by what our participants want and expect, and I think that has been really important for us in our history up to now as an organisation and increasingly in the future. Naimah: Yeah, and I think you've really highlighted how Genomics England were trying to keep the participants at the heart of everything that we do. Dr Nicola Byrne, the National Data Guardian for health and adult social care in England spoke about challenges with sharing health data and the importance of transparency and accountability in how data is used to support better outcomes from health and care services. “So, it's absolutely important that people feel that they can share that information and then feel confident that any information they do share is going to be used in ways that are safe, appropriate and ethical. Whether that's for their own care or thinking about the benefit of other people in future through research, innovation and planning.” Naimah: Well, let's get back to the interview for some final reflections with Rich. So, we've been looking back at our achievements over the last ten years, and I'll be keen for us to look at what's next. So, we've touched on it, but let's take some time to reflect on the research that has taken place across the global genomic landscape for example and, you know, what we've done here at Genomics England. Rich: The world has changed a lot in ten years. We've learnt a lot ourselves as an organisation and the researchers that work with our participants data and the national genomic research library have done extraordinary work. So, to give you a flavour of the sorts of things that I guess have changed in terms of what we can enable them doing in terms of research and research work. When participants data enters the research library they're consenting to their genomic data sitting there alongside deidentified clinical data from their longitudinal health records. As I said through our multimodal cancer initiative we're also now able to bring in image data for our cancer participants. And increasingly, and this is something that Matt Brown, our chief scientist, was talking a lot about at our research summit in September, was bringing in additional modalities of data alongside that. So, for example, in our rare disease participants bringing in proteomic, transcriptomic and long read data alongside the current sets of data. It means that that resource becomes even more powerful and able to answer a broader set of questions and able to ask questions across a broader set of data in terms of what might be useful for improving the understanding of medical conditions and improving clinical care. So, for example, there has been amazing work over the last few years on cancer and the mutational signatures that are there in tumours. For example, Serena Nik-Zainal's group understanding the patterns of mutation that are there in tumours driven by the underlying biology, not just because it helps us understand how things have happened, but also because it helps us understand about prognosis and how to treat conditions. We've got really exciting early insights from the work on the image data, that multimodal data, working as I said with academia and also looking at the work that insitro are doing. Recognising patterns between you can see down the microscope of a tumour and the genomics. To understand some of those processes that we've just not been in a position to explore before. And I think one of the really powerful pieces of work that is ongoing and will continue to is the ability for researchers and teams within Genomics England to continue to look for answers as our knowledge improves. So, some of the research work that we're doing is discovering some new fields if you like of understanding. We also know that each year literally hundreds of new genes linked to rare conditions are identified. So, enabling research that allows us to go back and look in our existing participants data to see if that new knowledge, that new knowledge about gene to condition links or better understanding of genomic variation means that we can keep looking for and finding things relevant to people who at the moment are research studies, 100,000 Genomes Project, or the Genomic Medicine Service initial testing with today's knowledge or the knowledge of today or whenever their test was couldn't identify because of the limitations of knowledge. Now we can go back and identify through by sharing likely insights of clinical importance with NHS laboratories. We can then pass those findings back to participants and that has been the case in more than 2,000 of our 100,000 Genomes participants already and it's enormously powerful. I think as we think about the direction of travel in the future, I think thinking about how we make sure that the breadth of questions that can be addressed for our participants in the national genomic research library is even broader, is really important. And that's, as I say, something that's particularly bringing in other types of data alongside has been a really important part of. We're also looking to the future where as I say we're proud of the impact that there already has been, and the NHS Genomic Medicine Service is the first national healthcare system to offer whole genome sequencing and that is extraordinary. Thinking about how we can broaden our impact is a really important part of that, and that's thinking about how we can be supportive of genomic technologies broader than just whole genome. So, for example,  panel and exome data and thinking about some of those other modalities of data like transcriptomes is really important as well for us. And that's something that we're exploring at the moment how we best do that, how we might do that. Also thinking about the range of settings that genomics is currently playing a role and we can see a future in five to ten years' time where rather than genomics being something where it plays a role in a small proportion of healthcare encounters where it could be impactful, over a much larger proportion, perhaps even up to a half of all healthcare encounters through, for example, pharmacogenomics potentially. And our Newborn Genome Programme is developing evidence that will help us understand whether that whole genome sequencing should be offered to all newborns. Potentially in research studies like Our Future Health are asking questions around the value of integrated or polygenic risk scores. Through those sorts of elements we can see genomics playing a role much more broadly both in terms of the number, proportion of clinical settings where it's relevant, much more towards it being a routine part of healthcare, but also across the lifetime at different stages and thinking about the value of genomic data if you like through the life course as something that can be looked at repeatedly increasingly without requiring specialist knowledge from the clinical teams so that it can have the impact it can. And thinking about how we might play a role in developing that evidence but also supporting the infrastructure through our expert knowledge in the management of coherent national genomic data sets. And also having that dialogue in public about how genomic data might be used and working out how we generate evidence that can drive policy change. I think there is enormous potential in the future and we in the UK I think remain uniquely placed to explore those sorts of questions. Naimah: So, we'll wrap up there and that brings us to the end of our podcast for 2023. Thanks to Rich Scott for sharing his reflections on the last ten years of Genomics England and his aspirations for the future. Moving into the new year we'll leave you with a powerful quote from our podcast with Dr Francis Collins who is renowned for his landmark discoveries and leadership in the Human Genome Project.  “My dream Chris is that we come up with in the next decade a scalable approach to every genetic disease where you know the mutation.” You can find all of the podcast episodes mentioned in this podcast plus many more on our website www.genomicsengland.co.uk or on your favourite podcast app. We look forward to bringing you some new episodes with more exciting guests in the New Year but do get in touch if you have any topics you would like us to cover. I've been your host Naimah Callachand, and this episode was edited by Mark Kendrick at Ventoux Digital. Thank you for listening.  

Kat Marran is currently the Interim Chief Executive Officer for the Girl Scouts of Greater Atlanta. She started her new role officially on July 12 and brings a wealth of corporate experience from a successful 29-year career at United Parcel Service (UPS.) She recently retired from her UPS role as Vice President of Marketing where […]

Kat Marran is currently the Interim Chief Executive Officer for the Girl Scouts of Greater Atlanta. She started her new role officially on July 12 and brings a wealth of corporate experience from a successful 29-year career at United Parcel Service (UPS.) She recently retired from her UPS role as Vice President of Marketing where […] The post Kat Marran With Girl Scouts of Greater Atlanta appeared first on Business RadioX ®.

For over two decades, Rebekah has held a global presence through devoting her efforts to various nonprofits and organizations. Her background is diverse, including educational and mental health content development, international relations, and public speaking.Currently, Rebekah is the Interim Chief Executive Officer of NPE Friends Fellowship, an international non-profit organization which assists individuals, and their families, who have received unexpected results from an at-home DNA test.Rebekah is also a consultant, writer, and advocate at RebekahDrumsta.com with the mission of supporting survivors of spiritual abuse and religious trauma by providing resources to educate and equip not only survivors, but the public as well. Sharing her own story to help others who have had similar life experiences is at the heart of Rebekah's purpose. She is a board member with two non-profit organizations The Vashti Initiative and the Attachment and Trauma Network. Rebekah's hobbies include binge watching riveting shows, thrifting with her family, international travel, and dabbling in all things creative and artistic. Rebekah and her family reside in Texas. Rebekah holds undergraduate and advanced degrees in: Urban Ministry and Family Crisis, Counseling, and Religious Education and is also a Certified Professional Life Coach. She has made appearances on and consulted with sources including BBC, NBC and ABC, and a variety of other platforms such as podcasts and film projects. Rebekah's book, When Family Hurts: 30 Days to Finding Healing and Clarity, was released in December of 2021. She is a co-author of the research paper, Percentage of U.S. Adults Suffering from Religious Trauma: A Sociological Study, as well as an author in the 2023 collaborative book, Hope in the 2020s: Encouragement for our time.Credit: www.rebekahdrumsta.com/aboutInstagram: rebekahdrumstaFacebook: DrumstaRebekahTwitter: DrumstaRebekahWebsite: rebekahdrumsta.com Hosted on Acast. See acast.com/privacy for more information.

In a world filled with uncertainty, Linda Gibson's journey proves that embracing comfort can unlock extraordinary possibilities. From a math major questioning her career path; to the unexpected twist that led her to become the CEO of an asset management firm, Linda's story is a testament to the power of taking leaps. Brace yourself as we dive into the captivating tale of Linda's relentless pursuit of growth and the surprising turn of events that would redefine her professional trajectory. In this episode, you will be able to: Unleash your potential by embracing change and seizing opportunities in your professional life. Discover the power of emotional intelligence and how it can enhance your success in the tech-driven world. Navigate the challenges and maximize the benefits of hybrid work environments through effective video communication. Unlock new possibilities and reimagine your career development strategies for the new age of work. Over the years, Linda took calculated risks and explored new avenues, ultimately rising to the position of Chairman and CEO at PGIM Quantitative Solutions. Her diverse experiences and willingness to take risks have not only led to her own personal growth and success, but also serve as an inspiration for professionals seeking their own path to growth. Get ready to be inspired by Linda's incredible journey on this episode of Beyond Barriers Podcast. Highlights: [00:00] Introduction to Beyond Barriers podcast [01:53] Meet Linda Gibson [03:15] Taking Risks and Seizing Opportunities [05:14] Gaining Confidence through Challenging Experiences [08:07] Building a Diverse Resume and Seeking Growth [14:27] Embracing New Opportunities [15:01] Recognizing the Right Opportunity [17:46] Recognizing Unique Value Proposition [21:31] Embracing Change and Opportunity [28:31] The Power of Compassionate Conversations [30:04] Embracing Authenticity and Soft Skills [34:02] Embracing Technology and Building Relationships [37:48] The Future of Work and Hybrid Models [40:12] Benefits and Challenges of Hybrid Work [44:02] Building Social Capital and Advocacy in the Workplace [44:57] Lightning round questions Quotes: “Push yourself, get a little uncomfortable, embrace the discomfort.” – Linda Gibson “Change breeds opportunity.” – Linda Gibson “A lot of my success I attribute to EQ vs. IQ.” – Linda Gibson  “Even if you don't feel you're ready, raise your hand, take the risk and leap into that.” -Linda Gibson “You don't always have to master something before you jump into it. Take the opportunity, even if you're not sure if you'll be good at it, and surprise yourself. “ - Linda Gibson Lightning Round Questions: What book has greatly influenced you? - “No Bullshit Leadership” by Martin G. Moore What is your favorite inspiring quote or saying? - “Everything happens for a reason.” What is one word or moniker you would use to describe yourself? - Even-tempered. What is one change you've implemented that made your life better? - Prioritizing relaxation and sleep. What power song would you want playing as you walk out onto a stage? - “Girl on Fire” by Alicia Keys and “I Am Woman” by Helen Reddy About Linda Gibson: Linda Gibson is Chairman and Chief Executive Officer of PGIM Quantitative Solutions LLC. Linda was previously Managing Director and Chief Business Officer for PGIM Quant Solutions. In this capacity, she oversaw finance, business planning and management, strategic intelligence, project management, ESG governance, human resources, operational risk and cross-functional initiatives with the broader legal and compliance team under the PGIM umbrella. Prior to joining PGIM Quant Solutions, she served as Executive Vice President and Head of Global Distribution at OMAM, now Brightsphere Investment Group (“BSIG”). In prior roles at BSIG, she held various executive positions including Interim Chief Executive Officer, Chief Operating Officer, Head of Affiliate Management and General Counsel.  Prior to working at BSIG, Linda served as Senior Vice President and Senior Counsel of Signature Financial Group, Inc. Linda holds a BA in mathematics from Bates College and a JD from Boston University School of Law. She is a graduate of the Advanced Management Program at Harvard Business School. Links: LinkedIn: https://www.linkedin.com/in/linda-gibson/ Website: https://www.pgimquantitativesolutions.com/

This year as we celebrated our 10-year annivesary, the NHS celebrated a significant milestone of 75 years. In this episode we reflect on our journey over the last 10 years, including the impact of embedding genomic testing into the NHS, how it all started with the 100,000 Genomes Project, and how patients have influenced the shape of the Genomic Medicine Service today. Host Rebecca Middleton, Vice Chair of The Participant Panel at Genomics England is joined by Professor Dame Sue Hill, Chief Scientific Officer and Senior Responsible Officer for Genomics in the NHS, and Dr Rich Scott, Interim Chief Executive Officer for Genomics England in this special episode of the G Word.   "To date, we've had over 1,500 putative diagnostic variants returned to the NHS, so to our NHS genomic laboratory hubs, for further investigation, further discussion with clinical teams. About 80% of those have been returned to clinicians and therefore to patients to, for example, give them a diagnosis or to update the diagnosis that they've been given or make treatments available. That is a real positive benefit from that pipeline to individual patients."   Listen to the other episodes in our 10-year series: Shelley Simmonds, member of the Participant Panel at Genomics England, speaks to Louise Fish, CEO of Genetic Alliance UK, and Amanda Pichini, clinical lead for genetic counselling for Genomics England as they reflect on how the patient journey has changed over the last 10 years for those living with rare conditions. Dave McCormick, member of the Participant Panel at Genomics England is joined by Jenny Taylor, a valued member of our research community, and Professor Matt Brown, our Chief Scientific Officer, discussed the last decade of genomic research at Genomics England.   Transcript You can read the transcript below or download it here: Transforming-the-NHS-with-genomic-testing.docx   Rebecca: Hello and welcome to the G Word. My name is Rebecca Middleton and I'm the Vice Chair of The Participant Panel at Genomics England. On today's episode, I'm joined by Professor Dame Sue Hill, Chief Scientific Officer and Senior Responsible Officer for Genomics in the NHS, and Dr Rich Scott, Interim Chief Executive Officer for Genomics England. Today we'll be reflecting on the last ten years of genomics, including the impact of embedding whole genome sequencing into the NHS, how it all started with the 100,000 Genomes Project, and how patients have influenced the shape of the Genomic Medicine Service today. If you've enjoyed today's episode, we would love your support. Please like, share and rate us on wherever you listen to your podcasts. Thank you, Sue and Rich, for joining me today as we look back at how genomics has developed in the NHS over the past decade and impacted tens of thousands of lives. It all started with the creation of Genomics England and it's first groundbreaking initiative, the 100,000 Genomes Project, which sequenced around 85,000 NHS patients affected by rare conditions or cancers and led to groundbreaking insights and discoveries for so many families. I'm one of those rare condition patients and my genome sits in the National Genomics Research Library besides thousands of others. Along with the project, I've been on a journey over the past ten years and I'm still hopeful that through time and further scientific discovery, my family and many others will get the answers they need for the future. Today is a chance to reflect back over the progress of the past ten years and to look forward about what's next for genomics, for genomic science, the genomic service, and for the patients and families it impacts. Sue, welcome. If we can come to you first, and it's a very big ask coming up, but can you briefly sum up your critical role in genomics over the past ten years and talk us through how you've shaped the service in the NHS to date? Sue: My role in genomics in the NHS has actually been much longer than ten years, because particularly genetic services have been part of the NHS journey since it was formed in 1948. As Chief Scientific Officer for England, part of my responsibility since I was first in that post in the Department of Health at that time and now subsequently in NHS England, but still with a crosscutting health and social care role, genetics and genomic services actually sit under the remit of the Chief Scientific Officer for England. Shortly after the 100,000 Genomes Project was announced and that the NHS would be a major contributor to the 10,000 Genomes Project, I was asked to lead the NHS contribution to the 100,000 Genomes Project. My role has been both of leading the NHS contribution to the 100,000 Genomes Project, and then as Senior Responsible Officer for Genomics in the NHS in introducing the NHS Genomic Medicine Service to the NHS and its subsequent role in delivery and in supporting research and other initiatives. Rebecca: Rich, over to you. Ten years ago I believe your role was very different and you were in clinic, so how has it changed over the past decade as genomics has embedded itself into the NHS? Rich: That's right. As you say, I'm a doctor by background and ten years ago I was consultant in clinical genetics at Great Ormond Street, where I still practice, I still do one clinic a month, but my role is primarily sat there meeting families with a child normally with some symptoms or some problems which people thought might be those of a rare condition and thinking about how we did that testing. At that time I was beginning to think about how we use in Great Ormond Street some of the newer technologies that were coming along. Using, for example, gene panels to help diagnose children who had epilepsy of early onset. Eight years ago, I joined Genomics England, where I could see the work of Genomics England and the partnership with NHS to deliver the 100,000 Genomes Project was something where at national scale we could do something, which at that stage I was just thinking about within one hospital setting. That's really changed things for me in clinic, but also my role in that has changed. I joined Genomics England originally as the clinical lead for rare disease, so bringing that specialist clinical expertise to give advice on how we establish the rare disease component of the 100,000 Genomes Project. More recently, in my role as Chief Medical Officer, I'm actually now as interim CEO thinking about how we've made that transition from the learning that we've gained through the 100,000 Genomes Project to working in partnership with the NHS and Sue and team to play our role in supporting their NHS Genomic Medicine Service. The next phase, if you like, or questions for us to make sure that we are still thinking in a forward looking way about how genomics can do what we believe it can do to be really there in the mainstream for everyone in terms of healthcare. Rebecca: And it really has been quite a journey over these past ten years, moving from a research project with 100,000 Genomes Project to a live clinical service and all the challenges that that must bring. Sue, what are you most proud of, what are those challenges that you've had to overcome and how do you see genomics medicine service moving forwards so it can help even more families? Sue: I think in answering your question, first of all, the Genomic Medicine Service is much broader than the whole genome sequence service that is delivered in partnership with Genomics England, and I'll come back to that. In terms of what I'm most proud of, I think when we started the 100,000 Genomes Project there was a view that we shouldn't involve the whole of the NHS in recruitment and in feedback to participants. I pushed really hard to have the whole of the NHS involved, recognising that if we were going to enter into a transformative project particularly for the use of cutting edge technologies by whole genome sequencing and the analytics that went alongside that, if we only started with a small number of centres we wouldn't get the transformation that was required within a whole health system. I'm really proud of the NHS contribution because the number of patients that were recruited over the period of time where we didn't start active recruitment until 2013 and then we completed early in 2019, to deliver this from routine care in the NHS in terms of recruitment and then for feedback I think is something that is unsurpassed by many other research projects, let alone research initiatives in genomics across the world. So while this is a world leading project, it's also I think a world leading contribution from the NHS from its routine care position. I was also proud myself to be a participant in the 100,000 Genomes Project within the cancer arm of the project and being able to speak at different public events around the benefits of sharing data through the National Genomics Research Library, in that it's a benefit that is much broader than you as an individual and has the potential to impact on thousands of people. The other thing I'm most proud of is introducing the NHS Genomic Medicine Service because we still remain in the NHS world leading. Of course, a key part of that is that we have whole genome sequencing now available within routine care, within the NHS for patients with rare and inherited disease and cancer. Obviously not for all of those patients, but for the group of patients that fit within those broad-brush clinical groupings where there is the most need, but also the ability to deliver a diagnosis compared to what we could do from standard of care testing. I think it's those two halves for me with myself being a participant and being part of the NGRL right in the middle. Because, of course, from the NHS Genomic Medicine Service, which is what many other countries are grappling with, as soon as you introduce a whole genome sequencing service within a health system, how do you also continue to support research and continue to populate a research database that can be accessible, access is approved and in a safe data environment, how can you continue to support that? Rebecca: Over to you now, Rich, on what you're most proud of for yourself, but also for Genomics England and being the custodian of people's data, that people have given their data through the 100,000 Genomes Project and they continue to give their data through the GMS. If you could pick up also on the research side, so the role that Genomics England has played in the development of the Genomics Medicine Service and the genomics within the NHS, but also in the wider ecosystem as well in terms of driving discovery and driving answers for the many families and for many patients out there who are still looking for those answers. Rich: I think really there is one word that I come back to quite a lot which is the word together, where the journey that we've been on as Genomics England, me playing my role at Genomics England, but all of those involved across the ecosystem, that key partnership that we have with the NHS and with our participants, but also broader than that into the other people involved in delivering a live clinical service now that we support the whole genome element of. Also, collaborators in research, whether that's in academia or industry, this is a team sport. What I'm proud of most is the impact that we've had together and recognising that when this journey started there was a real vision about the potential that genomics could bring in the coming years because of the changes that came. For example, the next generation sequencing technology, but also the changes in ability to hold and analyse data at scale. I think rightly no one would have pretended to know what the journey was. I think the thing I'm most proud of is that we have navigated that together. In a way, we've continued to learn and we've learnt from the challenges that we have encountered, whether it's through delivering the 100,000 Genomes Project or our work since, because there always will be challenges. The reason that we're so proud of the impact that there has been is because we recognise it's hard to do. I think that point particularly of linking healthcare and research is absolutely key. That's something that we're working with Sue and the teams across the NHS are absolutely committed to and recognising that this is an ongoing learning area. That means learning how we do every element of it, but it also means that marrying clinical care and research is absolutely critical to getting the best outcomes for the system as a whole and for participants/patients individually. We've learnt how to set up a system that works in that way. We've worked through the consent models that patients in the NHS receiving routine care are comfortable with. The models of presenting data de-identified for researchers to use for purposes that those participants are comfortable within, as we call it, a trusted research environment, is a model that comes with challenges in terms of the data access for researchers but is one that is really broadly accepted and we can get to work at scale. I think it's that ongoing learning and that we've now I think shaped an approach to genomics across clinical care and research which no one would say is perfect, but we definitely understand that we've learnt about a model that we can keep iterating on and, crucially, we'll keep learning for participants present and future. So that, as you say, Rebecca, one example of that situation is where families have had a test, whether that's through 100,000 Genomes Project or more recently through the NHS Genomic Medicine Service, if today's knowledge can't find the answer in terms of a rare condition diagnosis, we know that one really important element of that research offer is that researchers will continue to look for answers. If something is found that is relevant, that can be fed back to the clinical laboratories to look at. If there is something that is clinically actionable, that can be reported. Rebecca: Thank you, Rich. I suppose, Sue, we've had a decade of navigation, a decade of learning and a decade of adapting to really take us from the 100,000 Genomes Project to the NHS Genomics Medicine Service. There have been challenges along the way, no less we've had COVID to deal with, a global pandemic. What other challenges have you had to overcome to embed a workable world class service within the NHS, how have you navigated that with your partners such as Genomics England? Sue: What's been really important is actually understanding the challenges. I see the challenges more in the sense of the transformation that we need to drive rather than them actually being challenges. Some of the transformation that was driven through the 100,000 Genomes Project we've actually baked into the Genomic Medicine Service. For example, during the 100,000 Genomes Project we understood the importance of clinical leadership; particularly if genomics was going to be embedded across the NHS for patient benefit, then it would involve more clinical specialties than clinical genetics. Through the 100,000 Genomes Project, we really drove leadership and engagement across multiple clinical specialties. We also drove this whole model that Rich talked about earlier about data sharing for broader benefit, and that benefit has then transferred over into the Genomic Medicine Service. We also recognise that if we were going to hold genome sequence a number of the processes, technical processes that happen within now our genomic laboratory hubs, needed to be standardised with quality and also external quality assurance at the core. That's right from taking a sample from a patient, extracting DNA, the sequencing methodology, whatever that is, whether it's whole genome sequencing of the type of testing within the NHS, so large gene panels, whole exome sequencing, or even smaller gene panels and other types of testing, that had to be consolidated and standardised. When results are returned we needed a standardised approach to results and interpretation. Across all of those areas if we're trying to drive a national approach as we were in the 100,000 Genomes Project and we're now in the Genomic Medicine Service is having an external quality assurance process that can look externally at each of those components that has been an important learning from the 100,000 Genomes Project into the Genomic Medicine Service. A key other element of transformation, and I hope you'll agree with this, Rebecca, was the involvement of members of the public and also participants. So right through the 100,000 Genomes Projects from Genomics England establishing The Participant Panel, through to the involvement of patients and public throughout the national programme for the 100,000 Genomes Project in NHS England, through to the genomic medicine centres that we created at that time, all of that has now been reproduced in the Genomic Medicine Service. So, patient and public involvement is a key part of the delivery mechanism. Finally, we've had to change and continually adapt and develop the underpinning data and digital infrastructure in the NHS. Initially in the 100,000 Genomes Project we standardised the data that was collected for rare disease. We introduced the use of terms called human phenotype ontology system that enabled individual patients and their presenting characteristics to be classified; that's continued on into the Genomic Medicine Service. But still more work to do in the 100,000 Genomes Project, we have to get multiple informatic systems to talk to one another. As we moved into the Genomic Medicine Service, we've both with Genomics England had to develop the analytical pipeline. We've had to develop a system that's enabled whole genome sequencing, for example, to be ordered and then to be returned after sequencing and the semi-automatic analytical pipeline in Genomics England to generate a report that could then be looked at and interpreted in the genomic laboratory hubs and returned to patients. What's been a key part of that has also been the establishment of genomic multidisciplinary team meetings that came out of the 100,000 Genomes Project, but now is embedded into the Genomic Medicine Service. Of course, the difference between the 100,000 Genomes Project contribution and now in the genomic medicine service is to ensure there's equity of access across the country in terms of the testing that is provided. A key part of the way in which the testing is offered is that introduction of the National Genomic Test Directory that sets out the standardised offer that will be funded by NHS England. That's across where an inherited disease or cancers, as well as common diseases and some other pharmacogenomic applications. The challenge always is standardisation, equity of access, and the infrastructure and leadership that makes this happen, together with developing a workforce that is genomically enabled so that it can spread out beyond that clinical genetics specialty into those multiple specialties to make sure that it's embedded. So remain in terms of some of the challenges around making sure that we change clinical pathways where genomics means that we can do things much earlier on in a patient pathway and get a definitive result and intervene. This is particularly important in cancer, but it's not just cancer, it's also in rare disease. Secondly, it's about how do we develop the whole of the NHS workforce. We have 1.3 million people that are directly employed by the NHS. There are another 600 that actually are associated with the NHS through the contracts that they hold. It's a huge task that we still have to undertake to make sure that genomics is available to all. There are two other elements, one we have to continue to take the public with us, and I think we've learnt from COVID that the public does understand now the importance of molecular tests. But there's still more to do as we use genomic information more broadly across the NHS and to drive treatment decisions that might mean that a patient thought they were going to get one cancer drug but they're going to get another because their genomic mutation says treatment B might be better for them than treatment A. We have and will continue to have a number of ethical issues that will arise as we consider whether it's some of the research initiatives that are undertaken or whether it's some of the decisions that might be made within the NHS Genomic Medicine Service or for the use of genomics. That's just a few, but it pulls it together from what we've learnt from the 100,000 into the GMS, what else the GMS is doing, and what some of the challenges are that remain. Rebecca: And a great deal has been done. There are a number of key challenges ahead. As you say, it's been a learning process, it's been a navigation process, but it's been driven by the people, by systems, by people, and they have played a critical role and will continue to play a critical role in ensuring the success going forward. I sit as the Vice Chair of Rare Conditions on The Participant Panel. Rich, if I can come to you next, how has the patient voice, how has The Participant Panel but the wider patient voice been heard and how are their view, their needs being reflected in addressing these four big sort of buckets of challenges and how are we learning these lessons going forward thinking of the new projects? For example, the newborn genome project, The Generation Study, could you give us some examples of how that learning is going forward and we're learning from the past but preparing for the future? Rich: I think it comes back to one of the really key words here is transparency and transparency in a number of ways. One of those is about the fact that this is a journey we're all on together. So, one of the things that was there right from the beginning of the 100,000 Genomes Project before I arrived was putting participants absolutely at the centre of project and the design and then in time that came for us in Genomics England wider in terms of our organisational governance. Establishing The Participant Panel on which you're a co-chair I think was really important for us early on to make sure that participants whose data it is we hold, it's no one else's data, it's our participants' data, are there driving and at the centre of the decision-making process, for example, through our Access Review Committee around who accesses the data. Participants sit on various of our governance groups and that's a template which I think is one that people have seen in various fields as working really well. It's one that Sue has touched on as being looked at and has provided useful input as to how patient and participant involvement has been set up in the Genomic Medicine Service. I think recognising that much of this is us all collectively finding the right path forward is how we approach every question that we tackle. Sometimes that's around really very practical questions. So, for example, Rebecca, you will know we often come to you guys about how we phrase a letter that might go out to participants, because recognising that from the inside of an organisation you see things one way but you might not recognise some of the nuances that are really important. Through to thinking about the really important questions around how we should set up access and safeguards around access that are there and, again, having participants sat on our Access Review Committee is crucial. And on to finding our way in new areas where the Newborn Genomes Programme I think is a really nice example where in many ways it's quite similar to the 100,000 Genomes Project in that it's a research study and it's delivered in partnership with the NHS. It's asking big questions around whether genomics can be used in a particular setting and if so, how could we use it? I think a really critical part of that and one that's been, as you know, sat in a number of the different strands and in the overall governance for the programme, Rebecca, having participants guide us, whether those people who like yourself are already part of the national genomic research library or whether they're people who might join the study themselves, or whether they're people with a different perspective that is important to include, including that engagement work as well as just with the broader public as part of the study is absolutely crucial. Before we even started the design of the study we set out with a public dialogue around attitudes to do with genome sequencing in newborns jointly with the National Screening Committee to understand where public views were to allow us to do a bit of a deep dive, not just a superficial vox pop view on what's your attitude to a one-liner question, but really to work with people on understanding some of the nuances here. There's a lot of nuance in most of the questions that we're engaging with, and then through the programme into different elements, whether that's designing the materials for consent or whether it's understanding how to practically design the process for contacting families or feeding back findings as part of the study, making that part of the process rather than a separate endeavour I think is really crucial. One of the words that I often hear people use when talking about challenging questions around how we make advantages in medicine is around explaining what people are doing. I actually think that's a really interesting word which I don't like. Most of the time this is about dialogue and it's about discovering together what we are doing and it's not people sit in with the best of intentions and with great expert knowledge in a closed room to decide what's the best approach, which is often an easy way to think about how to design a research study, for example, but this needs to be an active process where there's genuine dialogue and we learn and find our ways together. Rebecca: Some great examples there, Rich, of how powerful the participant and the patient is in the designing future services for even more patient and participants going forward and ensuring how needs and views are reflected. But, Sue, it doesn't just happen in Genomics England, there are patients and participants across the GMSAs as well, which is fantastic to see and I sit on the panel at the East GMSA as well. How important was that for you to establish that as part of establishing the Genomics Medicine Service? How important was that for you to ensure that the patient and participant view was there locally as well? Sue: So, I think we learnt from the 100,000 Genomes Project about the importance of patients and participants being part of the research element of the 100,000 Genomes Project and how that was designed, how the different pathways were put in place. In NHS England the patient is at the centre of everything when we come to our services. In all of our major programmes we have patient representatives, patient for an ongoing discussion with patient groups. This was both building upon what we'd created together with the Genomics England Participant Panel in the 100,000 Genomes Project, but then making sure that it fitted with the new genomic medicine service infrastructure that NHS England commissioned from 2018 onwards. It was making it a key part of that, making sure that coproduction with patients and families and really having a temperature check on an ongoing basis about the experience of patients and families of the genomic medicine service that they were experiencing has been a key component of our infrastructure and how we've put the infrastructure together. I always think there is more we can do, there's more we can do to monitor the experience particularly of services. That having been said, we will continue to drive forward the involvement of patients and families in the future iteration of services, whatever that might look like. I think if you put patients and families at the centre, that actually helps you determine the type of services that need to be commissioned nationally, the type of concerns that people have of the service and the experience that's feeding up, but it makes sure that patients and public representatives are part of all the important governance groups. For me, that's where the conversation needs to happen, it needs to happen both at an individual service level but through all the levels of governance that actually govern a service that is commissioned by the NHS in England for the population that is being served. Even if we haven't got it totally right, I hope that we've got it as a key component of all of the services and set out in commissioning specifications such that it's a requirement as is having the technology in place to deliver a bunch of genomic tests. Rebecca: Thank you, Sue. The Genomic Medicine Service is unique in the way that it provides a clinical outcome that is an answer for a patient, and also includes the option of joining the research library which supports further discovery. What are the benefits of this? Sue: The positive benefit of having the National Genomic Research Library has been through the researchers, scientists who've been granted access to the data. To date, we've had over 1,500 putative diagnostic variants returned to the NHS, so to our NHS genomic laboratory hubs, for further investigation, further discussion with clinical teams. About 80% of those have been returned to clinicians and therefore to patients to, for example, give them a diagnosis or to update the diagnosis that they've been given or make treatments available. That is a real positive benefit from that pipeline to individual patients. But also the evidence that's generated enables us to evolve the genomic test directory. It enables us to add to genes if new genes have been discovered to the test directory, changes in eligibility criteria, so it's this continuous evolving learning system. From patients providing samples and their consent for their data to be used to the research library, to the feedback loop back into the NHS that influences both individual patient care, but also the type of tasks that get offered in the genomic medicine service overall. In conjunction with Genomics England we have also been working on an NHS Genomic Medicine Service research collaborative that's enabled us to look at the projects and initiatives that industry or other researchers would like to undertake, would like to have access to samples or to data, and to consider that on the basis of would this support the overall national endeavour in genomics, would it add to the National Genomic Research Library and create that learning system? Is it something that we need to do nationally rather than just locally in a research project? It's making the infrastructure available for those research projects over and above the ones that are part of Genomics England spending review initiatives or NHS England's Genomic Networks of Excellence. But enabling us to work with industry and researchers to support their research endeavours in a way that is contained and make sure that we create and continue to create and add to the National Genomics Research Library and this overall learnings infrastructure. Rebecca: And Rich, anything further to add there? Rich: I think that creation, that word, that learning infrastructure is the key thing there. I think the process that has taken us here where we've worked out how to integrate clinical care and research is so valuable, both for the individual patient and participant and also for the system as a whole, often making the choices that allow us to arrive in the direction actually all point together towards doing the same thing. It's really constructing things around that central vision and I think that is so important. Rebecca: Thank you so much. We've had a whistlestop tour of genomics over the past decade which and improved and informed the lives of thousands of patients and families. But to finish, let's look forward. What is your one hope for the future of genomics within the NHS? Rich, perhaps we could start with you? Sue: I think my wish is a relatively simple one, which is that we maintain this momentum that we've got and we've built together. We're on a journey and it's momentum towards genomics being absolutely part of the day-to-day, the mainstream of healthcare so that wherever you are in the country, whoever you are and often potentially without the clinical teams needing to feel they're doing anything very genomicsy, if you like, genomics is there and bound into the routine care that one has to deliver. I think when we look and we compare ourselves to other countries, because of that link that we've made and that partnership between clinical care and research, we are in a really strong position. It's therefore about maintaining that momentum and getting us to that place where genomics is just a routine part of everyone's care. Rebecca: And Sue, finally over to you, what is your one hope for the future? Sue: What I'm looking for when we put the patient at the centre is that we adopt all of the genomic technologies that would really enable us both to diagnose a genomic cause for patients that of presenting symptoms, or to inform their more preventative or inform their treatment such that genomics becomes part of everyone's pathway of care in the NHS, and that we really maintain the NHS Genomic Medicine Service as the most advanced service within the world and that it continues to work to populate a National Genomic Research Library with Genomics England such that patients can benefit from ongoing analysis and interpretation of their data. That we really become the leader across the world of this learning ecosystem and we give as many patients as possible a diagnosis and that we inform as many patients as possible treatment pathways. I believe we're in the next wave of genomics following the discovery of DNA in 1953, and now it's how do we make genomics available to everyone across where an inherited disease, across cancer, across common and acquired disease and in pharmacogenomics. Rebecca: Thank you to our guests, Professor Dame Sue Hill and Dr Rich Scott, for joining me today. It's been great to talk to you and understand the journey so far and what's ahead for genomic healthcare. Happy 10th birthday, Genomics England, and happy 75th birthday, NHS. Here's to the next decade of supporting patients and more scientific research and genomic discovery to drive home. If you'd like to hear more like this, please subscribe to the G Word on your favourite podcast app. I've been your host, Rebecca Middleton. This podcast was edited by Mark Kendrick at Ventoux Digital and produced by Naimah Callachand. Thank you for listening.  

October saw the Isle of Man Football Association appoint Lewis Qualtrough as its Interim Chief Executive Officer With a breadth of experience in FA roles to date, what does Mr Qualtrough think is needed to help grow the local game going forward? In this extended interview, we hear his priorities and thoughts around his latest FA position

Dane Peterson, Former Interim Chief Executive Officer at Emory Healthcare joins the podcast to discuss his latest work, Emory Healthcare being the first hospital in the country to treat the Ebola virus in 2014, and advice for hospitals and health systems who have a major hospital close near them.

Despite the sudden and unexpected departure of financial leaders at Hyndman Area Health Centers, new management was able to quickly improve their revenue processes by collaborating with eClinicalWorks. The Hyndman team is now more efficient, streamlined, and able to deliver financial information in a timely manner. Healthcare IT Today met with Dr. Brian Stratta, Interim Chief Executive Officer and Chief Medical Officer of Hyndman Area Health Centers (HAHC) to learn more. Learn more about Hyndman Area Health Centers at https://hyndmanhealth.org/ Learn more about eClinicalWorks at https://www.eclinicalworks.com/ Find more great health IT content: https://www.healthcareittoday.com/ eClinicalWorks is a sponsor of Healthcare Scene

Kate Duggan, Interim Chief Executive Officer at Tusla, discusses the challenges facing the Child and Family Agency as it publishes its 2022 Annual Report.

In this episode, I talk with two highly esteemed fire protection engineering professionals: Chris Jelenewicz, P.E., FSFPE, the Interim Chief Executive Officer at SFPE, and Stephen Dale, P.E., CFPS, ARM, the Director of Technical Services at The Cincinnati Insurance Companies. We explore the diverse world of fire protection engineering, discussing its scope, essential skills, and […] The post TECC 303: Fire Protection Engineering Unveiled: Skills, Career Paths, and Launching Your Journey appeared first on Engineering Management Institute.

You need to share bad news, a lay-off, a break-up, or even a death. How do you do it - with love and care?   For this Women of Color Rise episode, Analiza talks with Vanessa Rodgriuez, CEO of NYC Outward Bound Schools. Prior to this, Vanessa was the Chief Program Officer and Interim Chief Executive Officer at Citizens of the World Charter Schools (CWCS). She joined CWCS after serving as the Talent Officer of Newark Public Schools (NPS). Vanessa is also the proud mom of a fifteen-year-old son and she enjoys spending time playing basketball with him.   Vanessa has led many hard transitions and turnarounds, including layoffs at Newark Public Schools. She shares the keys to having a difficult conversation: Center care for the other person and that this care means honesty. “I care about you and want to be honest.” Just say it. Start with the “bad news” and then follow up to figure out solutions. Keep the mission front and center. Vanessa would remind herself that the mission is to serve students not provide employment. Consider the politics and front loading communication with other stakeholders to get buy-in before delivering the news.   Get full show notes and more information here: https://analizawolf.com/ep-44-just-say-it-how-to-have-a-difficult-conversation-with-vanessa-rodriguez  

This episode features Dr. Thomas Graf, Interim Chief Executive Officer at Renown Health. Here, he discusses what led him to Renown Health, the importance of staying consistent & connected with values, providing care in a more efficient way through pragmatic innovation, and more.

Have you been thinking about getting your Master of Business Administration (MBA)? What are some of the benefits of obtaining an MBA. We're joined by Interim Chief Executive Officer of the National Black MBA Association, Shawn Graham, who brings a wealth of knowledge and leadership in her 30 years of experience leading global and national corporations in various industries. In today's episode we'll talk about the current MBA landscape and what this means for underrepresented employees. In addition, we'll provide receipts on the current MBA pipeline and C-CRETS on the advantages of pursuing an MBA; before sharing how companies can build and expand their efforts to develop and recruit underrepresented employees.

This episode features Dr. Chris Thomson, Interim Chief Executive Officer at Longmont United Hospital. Here, he discusses his transition from ER physician to executive leadership, “doing what you love & calling it work”, and more.

As my grandma Moo approaches her 100th birthday, she tells me she wants a kitty. What grandma wants, grandma gets. So I start my kitty hunt, deciding that an older feline will do the trick. After hours of searching, I come across the dream kitty at Santa Barbara Humane. Her name's Maribel, and I fall in love with her immediately. But I can't get out that day to adopt her because of an Improv show I have to do that night. So I call and ask them to please hold on to this cat until the next morning. The person on the other end, however, lets me know that they have a first come, first served policy for adoptions. And she can't break the policy even after I explain that it's for my 100-year-old grandmother.  “If the kitty isn't adopted, she's yours first thing in the morning,” she says. So the next morning, my husband Mark and I get in the car in the pouring rain and make a stop at Petco for supplies on the two-hour drive to Santa Barbara Humane's Santa Maria Campus. When we get there I announce, “We're here to adopt Maribel.” Just then I notice another couple in the waiting area who says, “Oh, we're here to adopt Maribel too.” My heart sinks. We're five minutes too late from being first. This other couple goes into the room to meet Maribel. We wait. When they reemerge they share that she won't come out from under her chair to greet them, so they've decided to adopt another cat!  Hurray! Mark and I still have a shot at this and rush into the room. And wouldn't you know it? Just as we sit down on the floor, this dream kitty for Moo instantly comes right out, plops herself down in Mark's lap and starts purring away. (I secretly think she was hiding from the other couple on purpose because she knew we were the right humans to adopt her.) Happy endings to stories like that happen every day, and today's special guest gets to witness them personally. Kerri Burns is the CEO of Santa Barbara Humane. In this episode, she talks about what the Humane Society is all about, shares stories of some of the pets she's fostered, reveals the three different types of cats, and discusses how the organization in Santa Barbara works with animals and people to make sure adoptions are a great fit for both. She also answers curious questions like: How does a chihuahua in dire straits show the good intentions people can have? How is the Humane Society part of a bigger whole? And what amazing things does Santa Barbara Human do for animals (and humans)?  What you will learn in this episode: What it means to think from the paws up What misconception always comes up regarding stories of sheltered animals How you can help change the story for animals in shelters Who is Kerri? Kerri Burns has served several roles in the Humane Society and other animal rights organizations across the country. She was the Interim Chief Executive Officer and President of the Humane Society of Southern Arizona in Tucson. Then she served as the President of Pet Alliance of Greater Orlando before moving on as Interim Executive Director of the Tree House Humane Society in Chicago, Illinois. Previously, Kerri also assisted animals through some of the country's greatest animal disasters through Animal Emergency Services Programs for the American Humane Association. She's been recognized for her educational outreach on various animal welfare topics with the American Humane Association's Dennis White Award and for her management of charitable giving for PetSmart Charities®. Currently, she's the Chief Executive Officer for Santa Barbara Humane.

Market Outlook 2022 Moderator: Kaitlin Meyer, Vice President, Marketing & Sales, MIAX Panelists: Shawn Cruz, Director of Derivative Strategy and Trading, TD Ameritrade Ravi Jain, Chief Product Officer, Sterling Trading Tech Tommy Martin, Co-Head of Options, Dash (an ION Company) Patrick Zielinski, Interim Chief Executive Officer, BOX Options

Market Outlook 2022 Moderator: Kaitlin Meyer, Vice President, Marketing & Sales, MIAX Panelists: Shawn Cruz, Director of Derivative Strategy and Trading, TD Ameritrade Ravi Jain, Chief Product Officer, Sterling Trading Tech Tommy Martin, Co-Head of Options, Dash (an ION Company) Patrick Zielinski, Interim Chief Executive Officer, BOX Options

GUEST 1 OVERVIEW: Steve Clifford is CEO and passionate about helping people facing adversity to improve their opportunities in life. That passion has led him to work with organisations which transform the lives of vulnerable, disadvantaged and marginalised people. Steve was formerly in the corporate world after leaving law in early 2014. In March 2021, Steve became the Interim Chief Executive Officer of SecondBite after holding leadership roles in non profits. GUEST 2 OVERVIEW: Patrick Soosay is Manager of Harris Park Community centre. The Centre has been involved in the local community since 2003. Serving local the local community in the LGA. Programs consist of support, advocacy, Family Domestic Violence support, form filling, school holiday programs, health sessions, Justice of peace service to name a few. The Food pantry / parcel service which is provided weekly and is over subscribed. Patrick was born and raised in Singapore and has resided in Australia for 16 years. He has been in social work for 30 years, working with adults with disabilities and youths He has been Manager of the centre for over 7 years and sits on several Committees. 

On today's episode, we are joined by Stephanie McMahon, Interim Chief Executive Officer of the WWE. The WWE is literally in Steph's DNA. She is the fourth generation McMahon to carry on her family's tradition as a promoter, entertainer, and business executive. She got her start early, modeling T-shirts in middle school, and then stepped into the ring herself. Steph also held down office jobs, starting as a receptionist, working in sales, and then headed up WWE's creative, including storylines. In 2013, Steph became WWE's chief brand officer. During this episode, we discuss Steph's esteemed family legacy in sports entertainment and how she has blazed a trail for women in the squared circle and in the front office. Hosted on Acast. See acast.com/privacy for more information.

Dr. Kaleb Rashad is the Interim Chief Executive Officer of High Tech High. Kaleb is also the Co-Founder & Creative Director at the Center for Love & Justice located within the High Tech High Graduate School of Education (HTH GSE). In this role, he works with community leaders in the US, Canada, Spain, and Hong Kong to create new schools and redesign existing schools focused on advancing equity through Liberatory Project-based learning. This week's conversation covers: the people who have influenced Kaleb's work, including a new record of references to past guests; the importance of mixing good education design with justice and equity, and why the transfer of power, history, identity, and partnerships are key components to the process; the need to move from an improvement space to a transformational space; teaching people how to think, not what to think; asking about, and then focusing on what is meaningful learning for the students; why we need to make sure students and teachers are comfortable bringing their whole self to the classroom; and why historical context is important for understanding today's challenges especially through the lens of race.Questions? Thoughts? Feedback? Email us at  freerangehumanspod@gmail.com or Tweet us at @jal_mehta and @Rodroad219Fugitive Pedagogy - Jarvis Givens

This week on The Green Rush, Anne Donohoe and Sirita Wright are back with a new episode with guest Jim Gilligan, Interim Chief Executive Officer & Chief Scientific Officer of Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs.  Jim Gilligan Ph.D. has over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and CMC manufacturing. Prior to joining Tryp, Jim helped lead multiple bio-pharma and biotech companies, including Tarsa Therapeutics, Herborium Inc., and Unigene Labs, where he was responsible for the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies. Jim received his Ph.D. in Pharmacology and Toxicology from the University of Connecticut and continued his post-graduate education at the Roche Institute of Molecular Biology In this episode our hosts explore with Jim how Tryp is working to alleviate the suffering of patients with unmet diseases including, Fibromyalgia and binge eating disorders, the Company's ongoing clinical trials, drug development pipeline, and what's next in the psychedelic industry. So sit back and enjoy our conversation with Jim Gilligan of Tryp Therapeutics Links and mentions in the show https://tryptherapeutics.com/  Links to the guest's company and social media accounts Tryp Therapeutics Twitter: https://twitter.com/tryptherapeutic Tryp Therapeutics LinkedIn: https://www.linkedin.com/company/tryp-therapeutics/  Jim Gilligan's LinkedIn: https://www.linkedin.com/in/james-gilligan-94090211/  Show Credits: This episode was hosted by Anne Donohoe and Sirita Wright of KCSA Strategic Communications.   Special thanks to our Program Director Shea Gunther and Producer Nick Opich. You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels: Twitter: @The_GreenRush  Instagram: @thegreenrush_podcast LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/  Facebook: https://www.facebook.com/TheGreenRushPodcast/  YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

John Beaver is President & CEO of BIOLASE. At BIOLASE, John's vision is to raise a generation of kids not afraid of going to the dentist. He brings over 40 years of substantial leadership and technical experience in finance and business management for both public and private companies. His experience leading debt and equity fundraising efforts to elevate companies from start-up to commercial success has positioned BIOLASE for growth. At BIOLASE, John has a pulse on investor relations, using dentist education to establish lasers as the gold standard of care, and building cross-functional teams internally. When not charting the path for BIOLASE, you can find John rooting for the Houston Astros or heading to Texas to visit his grandkids. John Beaver was most recently the Company's Executive Vice President, Chief Operating Officer, and Chief Financial Officer. He joined the Company in 2017 as Senior Vice President and Chief Financial Officer. He assumed roles of varying responsibilities over the past few years, including Interim Chief Executive Officer of the Company. Mr. Beaver has a Bachelor of Business Administration degree in Accounting from the University of Texas at Austin and is a Certified Public Accountant. Mr. Beaver brings to the board extensive management, financial, and operational experience. -- Critical Mass Business Talk Show is Orange County, CA's longest-running business talk show, focused on offering value and insight to middle-market business leaders in the OC and beyond. Hosted by Ric Franzi, business partner at Renaissance Executive Forums Orange County. Learn more about Ric at www.ricfranzi.com. Catch up on past Critical Mass Business Talk Show interviews... YouTube: https://lnkd.in/gHKT2gmF LinkedIn: https://lnkd.in/g2PzRhjQ Podbean: https://lnkd.in/eWpNVRi Apple Podcasts: https://lnkd.in/gRd_863w Spotify: https://lnkd.in/gruexU6m #orangecountyca #mastermind #ceopeergroups #peergroups #peerlearning #collectiveintelligence #southerncalifornia #criticalmassbusinesstalkshow

Marty Wikstrom is a founding partner of Atelier Fund, an organization that specializes in the acquisition and development of luxury brands. She is a seasoned brand and retail executive with over three decades of experience in executive roles. She serves as a board director for the World Wide Web Foundation, Fortnum & Mason, Johnstons of Elgin, the Rug Company, Farrow & Ball, and Harrys of London, Ltd. Marty has also served as the Managing Director and Interim Chief Executive Officer of Harrods, making her their only female director in 182 years of business. Marty joins us today to share her remarkable journey in retail and leadership. You'll hear about her background and how her passion for sports, fashion, and leadership eventually led her to the world of luxury goods. She outlines the lessons she learned from being a part of a complex organization in the retail and fashion industry. You'll also gain insight on the importance of overcoming the fear of failure and the power of curiosity and hard work. “It wasn't competing against others but competing against myself—and a standard of excellence—that mattered to me.” - Marty Wikstrom This week on Kathy Sullivan Explores: The five-year-old Marty Wikstrom and her remarkable journey in retail and leadership Her early interest in fashion, sports, and leadership How expectations of women and girls have changed over time Marty's post-college career track to Nordstrom Why Marty stayed with Nordstrom for over 20 years What merchandising and sell-through mean Marty's move to England and becoming Assistant Managing Director at Harrods The most difficult change Marty made at Harrods The difference between an entrepreneurial and a public company What it's like to be a business leader in the hyper luxury world The NASA of watchmaking and what luxury means to Marty Unconscious bias and what it's like to be the only woman in a boardroom Marty's move to launch her own fund for developing luxury brands Why Marty feels happy about women entering leadership roles in organizations today Our Favorite Quotes: “When you look around in a room and no one looks like you, it might be by design.” - Marty Wikstrom “The things that sustained me in my life are extreme curiosity and hard work.” - Marty Wikstrom Connect with Marty Wikstrom: World Wide Web Foundation World Wide Web Foundation on LinkedIn World Wide Web Foundation on Twitter World Wide Web Foundation on Facebook Spaceship Not Required I'm Kathy Sullivan, the only person to have walked in space and gone to the deepest point in the ocean. I'm an explorer, and that doesn't always have to involve going to some remote or exotic place. It simply requires a commitment to put curiosity into action. In this podcast, you can explore, reflecting on lessons learned from life so far and from my brilliant and ever-inquisitive guests. We explore together in this very moment from right where you are--spaceship not required. Welcome to Kathy Sullivan Explores. Visit my website atkathysullivanexplores.com to sign up for seven astronaut tips to improving your life on earth and be the first to discover future episodes and learn about more exciting adventures ahead! Don't forget to leave a rating and review wherever you get your podcasts! Spotify IStitcher IApple Podcasts I iHeart Radio ITuneIn IGoogle IAmazon Music. See omnystudio.com/listener for privacy information.

Jeff Douglas speaks to Carl Yates, the Interim Chief Executive Officer at AFNWA and Chief Wilbert Marshall, chair of its board of directors, about what the latest proposal from government means.

Workforce Opportunities & Residency Cayman (WORC) levies CI$1 Million Plus in Fines Over Past 3 Years Public Health has released COVID-19 figures Condolences from the Cayman Islands Parliament on the passing of former St. Kitts and Nevis Premier, Vance Armory. Three ships in Port today – creating a buzz in downtown George Town. An Interim Chief Executive Officer has been appointed for the Cayman National Cultural Foundation (CNCF). --- Send in a voice message: https://anchor.fm/rcnews/message

Chris Holman catches up with ​Edythe (Edee) Copeland, Interim Chief Executive Officer, Michigan Works! Association, Lansing, MI, their ​topic for this segment, July is Disability Pride Month I understand July is Disability Pride Month. Why is it important to bring awareness to this issue? In addition to this being Disability Pride Month, this year also marks the 31st anniversary of the signing of the Americans with Disabilities Act. Why is this act so important? How does Michigan Works! serve individuals with disabilities? How has the Coronavirus pandemic impacted individuals with disabilities? How can our listeners learn more about the Michigan Works! Association and the Michigan Works! network? » Visit MBN website: www.michiganbusinessnetwork.com/ » Subscribe to MBN's YouTube: www.youtube.com/channel/UCqNX… » Like MBN: www.facebook.com/mibiznetwork » Follow MBN: twitter.com/MIBizNetwork/ » MBN Instagram: www.instagram.com/mibiznetwork/

Mr. Rafael (Rafi) Ashkenazi, is a former The Stars Group CEO and a future Executive Chairman of Hard Rock Digital. Previously a Playtech COO, he joined the Rational Group in 2013 and had been with the company that eventually became known as The Stars Group for seven years. Taking over as CEO in 2016, Rafi is widely recognized to have played an integral role in the business leaving an incredible footprint on all it's aspects. Mr. Ashkenazi, who initially joined Stars Interactive Group in January 2013 as Chief Operating Officer, is an experienced gaming industry executive who previously served as Chief Operating Officer of Playtech plc (LSE: PTEC), a global gaming software development company (Playtech), from January 2006 to January 2010 and then from September 2011 to January 2013, and as a member of the board of directors of Playtech from March 2006 to January 2010. From January 2010 to September 2011, Mr. Ashkenazi served as Vice President of Business Operations of Playtech. He was appointed Senior Vice President of Strategy for The Stars Group in April 2015, Chief Executive Officer of Stars Interactive Group in November 2015, Interim Chief Executive Officer of The Stars Group in March 2016 and then permanent Chief Executive Officer of The Stars Group in November 2016. Mr. Ashkenazi graduated with honors from Shenkar College in Israel where he earned a B.A. in Industrial Engineering.

At Talent Tribe we love learning new strategies and thought leadership from folks in different industries and sectors. Enter Aila Malik, Founder of Venture Leadership Consulting, Interim Chief Executive Officer for First Place for Youth and author. On this episode Aila shares her wisdom for developing and uncovering executive talent in the nonprofit world. Spoiler alert - her tools and strategies are applicable to all Talent professionals regardless of industry.

Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.

Today on The Green Rush, hosts Anne Donohoe and Lewis Goldberg are sitting down with Bill VanFaasen, interim Chief Executive Officer and Glen Leibowitz, Chief Financial Officer of Acreage Holdings, one of the best known multi-state operators in the U.S. cannabis industry. Following the recent transition of Kevin Murphy from CEO to Chairman of the board, The Green Rush team wanted to sit down with the new leadership to get an in-depth on where the company stands today and its growth strategy going forward.   In the conversation, Bill expands on how his experience has prepared him for his new role as interim CEO and filling Murph’s shoes, the recent restructuring of Acreage’s deal with Canopy Growth and offers updates on the Company including its entry into New Jersey. Additionally, both Bill and Glen expand how the restructuring will affect Acreage shareholders, the Company’s plans for its hemp holdings and how the COVID-19 pandemic has affected the business. Acreage is considered one of the bellwether MSOs of the American cannabis industry and investors monitoring the space will not want to miss this conversation.  So don’t sit back, lean forward and enjoy!  Glen Leibowitz, Chief Financial Officer of Acreage Holdings  Mr. Leibowitz has over 20 years of finance and accounting experience with expertise in building and scaling operations, improving controls, enhancing IPO readiness and working to manage an organization through accelerated business growth. During his 9 years at Apollo, Mr. Leibowitz  held various key roles within the finance organization including the accounting lead in taking the organization public in 2011. Under his tenure, he Implemented the public reporting framework, accounting policies and directed the company-wide Sarbanes-Oxley program. Prior to Apollo, Mr. Leibowitz spent almost 10 years at PricewaterhouseCoopers focused on multiple complex foreign registrant financial statements and client IPO documents across sectors including: alternative asset managers, Internet/software, telecommunications, pharmaceutical, and mining. Mr. Leibowitz serves on the board of directors and is the audit committee chair for PowerPlay NYC, a not-for-profit organization dedicated to inspiring and educating girls through one-of-a-kind sports and academic enrichment programs. Bill’s VanFaasen, Interim CEO of Acreage Holdings Bill VanFaasen first served as Chairman of Blue Cross Blue Shield of Massachusetts from 2002-2007. He served as interim President and CEO from March-September 2010. In 2010 he was elected Chair of the Board of Directors for the second time, retiring in March 2014 when he was named Chair Emeritus. Bill joined Blue Cross in 1990 as EVP and COO. He served as President and CEO from 1992-2004 resigning as President and served as CEO until 2005. He was SVP of Operational Services at Blue Cross and Blue Shield of Michigan, serving in operational, marketing, and health care capacities over 20 years Links to guest’s social media: Glen’s LinkedIn: https://www.linkedin.com/in/glenleibowitz/Acreage Twitter: https://twitter.com/AcreageCannabisAcreage LinkedIn: https://www.linkedin.com/company/acreageholdings/Acreage Instagram: https://www.instagram.com/acreageholdings/ Links and Mentions: Acreage website: https://www.acreageholdings.com/about-us/Canopy/Acreage update: http://investors.acreageholdings.com/file/Index?KeyFile=404447631 Show Credits: This episode was hosted by Anne Donohoe and Lewis Goldberg of KCSA Strategic Communications. Special thanks to our Executive Producer Nick Opich and Program Director Shea Gunther. You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels: Twitter: @The_GreenRush  Instagram: @thegreenrush_podcast LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/  Facebook: https://www.

030: Nonprofit Leadership in Uncertain Times (Angela Woods)SUMMARYAs the COVID-19 situation descended on her organization with stunning speed, Angela Woods knew she would have to make critical strategic decisions without the luxury of time to thoroughly evaluate options or wait for additional data. Like so many nonprofit leaders right now, she had to rely on her instincts and experience to best “triage” an evolving situation. How she’s managed these circumstances so far is a great study in leadership in action and offers practical ideas and advice for nonprofit leaders at all levels facing similar uncertainty. Angela and I discuss how she rallied her staff, how she adjusted the mechanics of her board, how she adapted her short-term programming, and how she now views her strategic plan going forward. Typical of a good leader, she’s found ways to utilize the current challenges as a means to explore new opportunities for her organization and the girls it serves.ABOUT ANGELAAngela Woods brings over 20 years of combined for-profit and not for profit leadership experience to the Girl Scouts movement and serves as the CEO of the Hornets’ Nest Council in Charlotte, NC. Leveraging her experience as a strategist, she has increased the Council's market visibility, increasing corporate support and individual giving and led the technology platform redesign. Prior to leading the Hornets’ Nest Council, Angela served as the Chief Executive Officer for Girl Scouts Heart of the South in Memphis, TN. Before this appointment, she served as the Interim Chief Executive Officer and COO of the United Way of the National Capital Area (UWNCA) in Washington, D.C. and she also worked for United Way of Central Carolinas where she served as the Senior Vice President of Community Building & Administration. Preceding that, she worked at Bank of America in the areas of institutional trusts, retirement planning and investments, and global finance recruiting. Angela serves on the Board of Directors for two nonprofit organizations: Charlotte Merchants Foundation and Apparo, and in 2015, the Mecklenburg Times named her as one of 50 Most Influential Women in Charlotte. EPISODE TOPICS & RESOURCESSherrell Dorsey’s newsletter ThePLUGMalcom Gladwell’s book BlinkGreg McKeown’s book Essentialism

Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.

Mother, wife, scholar, diplomat, and fierce champion of American interests and values, Ambassador Susan Rice powerfully connects the personal and the professional. She joined us with stories from Tough Love, a powerful recollection of the experiences that taught her how to compete and excel as an African American woman in settings where people of color are few.  In conversation with Sally Jewell, former Secretary of the Interior and current CEO of The Nature Conservancy, Rice offered an insider’s account of some of the most complex issues confronting the United States over three decades. They discussed topics ranging from “Black Hawk Down” in Somalia to the genocide in Rwanda and the East Africa embassy bombings in the late 1990s, to Libya, Syria, a secret channel to Iran, the Ebola epidemic, and the opening to Cuba during the Obama years. Rice revealed previously untold stories behind recent national security challenges, including confrontations with Russia and China, the war against ISIS, the U.S. response to Russian interference in the 2016 election, and the surreal transition to the Trump administration. Above all, Rice and Jewell offered us an urgent appeal to the American public to bridge our dangerous domestic divides in order to preserve our democracy and sustain our global leadership. Susan Rice served as the 27th US Ambassador to the United Nations and is a former United States National Security Advisor. She is currently Distinguished Visiting Research Fellow at the School of International Service at American University, a Non-Resident Senior Fellow at the Belfer Center for Science and International Affairs at Harvard’s Kennedy School of Government, and a contributing opinion writer for The New York Times.  Sally Jewell is the Interim Chief Executive Officer for The Nature Conservancy. Jewell previously served as U.S. Secretary of the Interior from 2013 to 2017. During her tenure, she was recognized for using a science-based, landscape-level, collaborative approach to natural resources management. Presented by Town Hall Seattle and NAAM. Recorded live in The Great Hall on October 14, 2019. 

Today we welcome to The B.I.Stander Podcast: Susan Rice with Sally Jewell  TODAY'S EPISODE IS SPONSORED BY: THE STREET FANTASY FOOTBALL FULL TIME FANTASY   The B.I.STANDER Podcast is a conversational podcast unique to Bainbridge Island and Seattle that covers culture, current events, humor, music, sports, technology, politics, island activities, environment, quality of life issues, wellness and just about everything else. The intent is to introduce interesting people, ideas, and conversations. We are not perfect and that's OK! Thank you for your understanding.  Our Podcast is brought to you by: Eagle Harbor Insurance Blue Canary Great Northern Electric Office Expats  Follow us on Facebook and Instagram Listen on Spotify, PlayerFM, Itunes, TuneIN, Castbox, and more! Music performed by Band of Steves of The Island Music Guild. Music performed by Ralph Reign 206-780-6911 lessons@islandmusic.org  *additional sound effects from https://www.zapsplat.com Today we welcome Mother, wife, scholar, diplomat, and fierce champion of American interests and values, Ambassador Susan Rice powerfully connects the personal and the professional. She joins us with stories from Tough Love, a powerful recollection of the experiences that taught her how to compete and excel as an African American woman in settings where people of color are few.  In conversation with Sally Jewell, former Secretary of the Interior and current CEO of The Nature Conservancy, Rice offers an insider's account of some of the most complex issues confronting the United States over three decades. They discuss topics ranging from “Black Hawk Down” in Somalia to the genocide in Rwanda and the East Africa embassy bombings in the late 1990s, to Libya, Syria, a secret channel to Iran, the Ebola epidemic, and the opening to Cuba during the Obama years. Rice reveals previously untold stories behind recent national security challenges, including confrontations with Russia and China, the war against ISIS, the U.S. response to Russian interference in the 2016 election, and the surreal transition to the Trump administration. Above all, Rice and Jewell offer us an urgent appeal to the American public to bridge our dangerous domestic divides in order to preserve our democracy and sustain our global leadership. Susan Rice served as the 27th US Ambassador to the United Nations and is a former United States National Security Advisor. She is currently Distinguished Visiting Research Fellow at the School of International Service at American University, a Non-Resident Senior Fellow at the Belfer Center for Science and International Affairs at Harvard's Kennedy School of Government, and a contributing opinion writer for The New York Times.  Sally Jewell is the Interim Chief Executive Officer for The Nature Conservancy. Jewell previously served as U.S. Secretary of the Interior from 2013 to 2017. During her tenure, she was recognized for using a science-based, landscape-level, collaborative approach to natural resources management. Presented by Town Hall Seattle and NAAM.

This week, we're taking a look back on a crucial oral evidence session which took place on Monday (2 September 2019). If we rewind back to November last year, the Social Affairs Policy Review Committee, a standing committee of Tynwald, committed to undertake an inquiry into the topic of suicide. The move came as part of its report on mental health here. The committee set out to look at: i) The adequacy of preventative measures; ii) The response of public services following instances of suicide; iii) The role and functioning of the Coroner of Inquests; and iv) The support available for those affected by suicide. The panel consists of David Cretney MLC plus MHKs Martyn Perkins and Julie Edge. Mr Cretney and Mr Perkins heard in public from the Minister of Health and Social Care David Ashford, and Dr Henrietta Ewart who is Director of Public Health. We hear that discussion in full, and we also listen to previous conversations on the topic, with Bill Henderson MLC and also with the then-Director of Community Care, Angela Murray. Incidentally, the panel will hear from Murray - now the Interim Chief Executive Officer of the Department of Health and Social Care - from 3:30pm this Monday (9 September).

Robert Hall has always had a passion for the consumer goods industry. After graduating from Oxford University in England with a BA in Physics and Mathematics and receiving his MBA in Marketing and Finance from the Wharton School at the University of Pennsylvania, he joined Nestle, where he gained marketing, sales and general management experience. Robert has also worked at other leading consumer goods companies including Procter & Gamble, Kraft, Nabisco (where he was he was the President of their Specialty Products Company and of Christie Brown & Co. Ltd. in Canada ), and Lenox (where he was he was President of Lenox Brands). After over 20 years in large corporations, Robert moved into the Private Equity business, but maintained his focus on consumer products. He became an Operating Executive of Palladium Equity Partners, LLC where he served as Chairman of Wise Foods as well as Interim Chief Executive Officer of Castro Cheese Company. He then moved to Centerview Capital and became a Managing Director at the firm, before assuming his current responsibilities as Chief Executive Officer of Ole Smoky Distillery in 2016. Robert has also served as a Director on numerous corporate boards. Firstly, for Ault Foods Ltd., a $1.3b dairy products company in Canada, where he was also the Chairman of the Management Resources and Compensation Committee. He then served on the board for six other private equity owned food companies including, Castro Cheese, Taco Bueno Restaurants, Chung’s Gourmet Foods, Custom Food Products, Wise Foods and Frozen Specialties. Additionally, he was an Advisory Board Member of Belmay, a private fragrance company. Currently, he serves on the Board and is the Chairman of the Nominating & Corporate Governance Committee of Glatfelter, a $1.6b NYSE specialty paper company. He is also on the Board of Yucatan Foods, a privately held guacamole company. Hall is now the CEO of Ole Smoky Distillery, the leading moonshine company in the U.S. and home of the world’s most visited distillery, where he has supported the company’s efforts to significantly grow sales. Just recently the company won the 2017 IMPACT Hot Brand Award for spirits brands, which recognizes Ole Smoky’s size and growth over the past year. Today, Robert and his wife, Liz, live in Sevierville, TN and have three adult children, Emma, Alistair and Duncan, whom they visit often.

Cassidy Phillips serves as Senior Vice President of Innovation at Implus Corporation and is the Founder of Trigger Point Performance, Inc. He serves as its Chief Executive Officer. He oversees product and business development and education for the Trigger Point division of Implus. Cassidy is a world-renowned presenter and biomechanical specialist concentrating on sports performance and injury prevention. He has 14+ years of experience as an entrepreneur, innovator and pioneer in the self-care channel. He founded Trigger Point in 2002 and served as Chairman. He served as Interim-Chief Executive Officer of Trigger Point Performance, Inc. Cassidy is a Global Fitness and Health and Wellness Speaker, Cross Fit Level 1 Trainer, ISSA Certified Personal Trainer and biomechanical specialist. Join us as Cassidy shares his mindset and a glance at his journey to becoming a Rockstar Entrepreneur by empowering people to be able to take care of themselves so that they can do things they never thought possible. Learn more about your ad choices. Visit megaphone.fm/adchoices

How to Harness Skills Service & Strategy Join Evelyn Ashley and John Monahon of Trusted Counsel with their guest experts, R. Eric McCarthey, Chairman of the Board of the Atlanta Chapter of the National Association of Corporate Directors and Michael Parides, Interim Chief Executive Officer and Chief Financial Officer to technology based companies, as they discuss how directors can make a difference and Chief Executive Officers can manage the Board to a company’s highest and best use.

On today's Community Connections w/ Jade Harrell: Who Who in Diversity and Who is Annie Malone today? First, Jade Harrell with Ericca Willis, Publisher of Who's Who Diversity in Color. Who's Who Diversity in Color profiles ethnic minority leaders, highlighting their professional endeavors, talents and ingenuity in an annual event and book. Get the details behind the well-timed book and specifics about the unveiling event happening May 14th, 2015 at Ballpark Village PBR 601 Clark Street, STL MO 60103 5:30pm - 8:30pm Also on the show, Jade Harrell welcomes William H. Young, Chief Executive Officer with the Annie Malone Children and Family Service Center. Most of us are familiar with the May Day Parade. However, most people have no idea that the Parade is a fundraiser to help decrease youth homelessness and prevent child abuse and neglect. Most people don't know that Annie Malone Children and Family Service Center (AMCFSC) hosts the parade and helps families in the community experiencing crises. The newly appointed Interim Chief Executive Officer of Annie Malone, William H. Young said that it's his mission to elevate awareness behind the purpose of the parade. New to his position he's eager to inform the community about Annie Malone Children and Family Service Center and the exceptional services they provide. CEO William H. Young said the Board of Directors of Annie Malone is charting a new direction and repositioning the Center for the future. With the Board's vision, Mr. Young has several goals and is ready to put them into action. All of the programs revolve around providing a safe and complete service to address the needs of children and families in crisis. Annie Malone is a proud member of the United Way. Be sure to save the dates: Saturday, May 2, 2015 – 12-3 p.m. – Ice Cream Social & Open House, 5355 Page Blvd., 63112 Sunday, May 17, 2015 – 1 p.m. – May Day Parade, 20th to 9th along Market St. in Downtown St. Louis.

On today's Community Connections w/ Jade Harrell: Who Who in Diversity and Who is Annie Malone today? First, Jade Harrell with Ericca Willis, Publisher of Who's Who Diversity in Color. Who's Who Diversity in Color profiles ethnic minority leaders, highlighting their professional endeavors, talents and ingenuity in an annual event and book. Get the details behind the well-timed book and specifics about the unveiling event happening May 14th, 2015 at Ballpark Village PBR 601 Clark Street, STL MO 60103 5:30pm - 8:30pm Also on the show, Jade Harrell welcomes William H. Young, Chief Executive Officer with the Annie Malone Children and Family Service Center. Most of us are familiar with the May Day Parade. However, most people have no idea that the Parade is a fundraiser to help decrease youth homelessness and prevent child abuse and neglect. Most people don’t know that Annie Malone Children and Family Service Center (AMCFSC) hosts the parade and helps families in the community experiencing crises. The newly appointed Interim Chief Executive Officer of Annie Malone, William H. Young said that it’s his mission to elevate awareness behind the purpose of the parade. New to his position he’s eager to inform the community about Annie Malone Children and Family Service Center and the exceptional services they provide. CEO William H. Young said the Board of Directors of Annie Malone is charting a new direction and repositioning the Center for the future. With the Board’s vision, Mr. Young has several goals and is ready to put them into action. All of the programs revolve around providing a safe and complete service to address the needs of children and families in crisis. Annie Malone is a proud member of the United Way. Be sure to save the dates: Saturday, May 2, 2015 – 12-3 p.m. – Ice Cream Social & Open House, 5355 Page Blvd., 63112 Sunday, May 17, 2015 – 1 p.m. – May Day Parade, 20th to 9th along Market St. in Downtown St. Louis.